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ABSTRACT OF DISSERTATION

MULTIVARIATE ANALYSIS TO IDENTIFY POTENTIAL BIOMARKERS
FOR PROGNOSIS AND TREATMENT RESISTANCE
IN HEAD AND NECK CANCER PATIENTS
It is estimated that nearly 50,000 individuals in the United States will be
diagnosed with head and neck cancer in 2017 (American Cancer Society
www.cancer.org). Ninety percent of oral cancers are head and neck squamous cell
carcinoma (HNSCC). Major obstacles in the treatment of HNSCC are recurrence
and treatment resistance, which contributes to increased mortality. Therefore,
there is increased need to determine genetic alterations in HNSCC that may be
ideal novel drug targets, and biomarkers to improve diagnostic and prognostic
testing.
Abnormal localization and overexpression of base excision repair protein
and transcriptional regulator Apurinic/Apyrimidic endonuclease (APE1) has been
associated with treatment resistance and poor prognosis. Therefore, we explored
mechanisms for how APE1 contributes to treatment resistance and increased
mortality in HNSCC.
Because oxidative stress heavily influences APE1’s expression and
transcriptional regulatory activities, we examined genes involved in oxidative
stress management, including SOD3 and NRF2. PPARGC1A, a NRF2
transcriptional co-activator, was also examined as our lab previously observed a
link between APE1 and PPARGC1A expression. This previous work also revealed
that APE1 suppressed gene expression of tumor suppressor, decorin (DCN).
To examine possible mechanisms for how APE1 regulates expression of
tumor
suppressors
and
antioxidants,
digital
image
analysis
of
immunohistochemistry staining was used to identify alterations in protein
expression. Nuclear and total cellular protein expression of APE1, DCN, NRF2,
PPARGC1A, and SOD3 were quantified in regions of proximal benign, carcinoma
in situ (CIS) and invasive HNSCC. Patient survival analysis revealed that
increased APE1, DCN, and PPARGC1A protein levels were significantly
associated with reduced survival in CIS, benign, and invasive tissues respectively.
Using multivariate analysis of protein expression, we identified that increased
APE1 protein levels in the CIS of primary tumors were associated with the

presence of cancer invaded lymph nodes. Elevated DCN and SOD3 protein levels
in benign tissue were associated with poorly differentiated tumors as was reduced
PPARGC1A in CIS.
Most importantly, potential prognostic biomarkers for use in early cancer
development were identified. Identifying poor prognosis in early cancer
development allows the possibility of improved treatment strategies, which could
prevent invasive cancer development, and increase patient survival.

KEYWORDS: Head and Neck Squamous Cell Carcinoma, APE1, Digital Image
Analysis, Biomarkers, oxidative stress, concomitant CIS with invasive
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Chapter 1:

Multivariate Analysis To Identify Potential Biomarkers for

Prognosis and Treatment Resistance in Head and Neck Cancer Patients

1.1

Introduction

1.1.1 Overview of head and neck cancer
Head and neck cancer is the 8th most common malignancy in the United
States, and an estimated 50,000 new cases will be diagnosed within the United
States in 2017 (American Cancer Society www.cancer.org). Oral cancer
disproportionally impacts Kentucky. Between 2009-2013, oral cancer incidence
was roughly 1.2 fold higher than the national average and was highest in the nation
(1,2) (Figure 1-1). The age-adjusted incidence rate of oropharyngeal cancer was
11.3 per 100,000 people [95 % confidence interval (CI) 11.3 – 11.4] in the US and
13.8 per 100,000 people [95 % CI 13.3, 14.2] in Kentucky. Kentucky also has
increased mortality as a result of head and neck cancer, with 2.9 per 100,000
deaths in the state versus 2.4 per 100,000 people in the nation (SEER & NPCR,
Kentucky Cancer Registry) (1).
Approximately 90 % of head and neck cancers are squamous cell
carcinoma, which are referred to as head and neck squamous cell carcinoma
(HNSCC)(3). Impacted areas include the mouth, tongue, pharynx, nasal cavity,
and sinuses. Major risk factors include tobacco and alcohol usage, and human
papillomavirus (HPV) infection. These cancers have a high rate of recurrence and
often develop treatment resistance.

1

Figure 1-1: Disproportionate rates or oropharyngeal incidence and related
mortality in the state of Kentucky
The state of Kentucky has one of the highest incidence and mortality rates
associated with oropharyngeal cancer. Kentucky has an age-adjusted incidence
rate of 13.8 [95 % CI 13.3-14.2] compared to the national rate of 11.3 [95 % CI
11.3-11.4]. Additionally, the mortality rate is increased at 2.9 [95 % CI 2.7-3.2]
deaths per 100,000 people relative to the national rate of 2.4 [95 % CI 2.4-2.5]
deaths per 100,000 people.
(Figures generated by statecancerprofiles.cancer.gov on 10/19/16).

2

1.1.1.1 Current treatments for head and neck squamous cell carcinoma and
their limitations
Earlier stages of HNSCC are often successfully treated with surgery and
radiation (4,5). Late stages can be resected and are typically treated with platinumbased chemotherapy, and radiation (5,6). Surgical resection is frequently used in
disease management, but procedures can lead to compromised function and
severe cosmetic damage. When possible, minimally invasive procedures are
performed using laser therapy, and robotic assisted surgeries (4).
Radiation therapy occurs over the course of 7 weeks, with 5 doses of 2 Gy
given over each week (4). However, radiation therapy is not without complications.
Repeated radiation exposure damages healthy tissues, which can lead to delayed
wound healing and can complicate recovery from any future operations (7-9).
Radiotherapy can induce loss of function of the salivary glands, and thyroid.
Patients may also experience dysphagia, forcing them to rely on feeding tubes (6).
There are multiple chemotherapeutic options including platinum-based
compounds, antimetabolites, and taxanes (5,10). The immunotherapy drug
Cetuximab is used to inhibit epidermal growth factor receptor (EGFR), which is
commonly overexpressed in head and neck cancers (5,11). However, these drugs
are not without risk, and treatment resistance is still an issue. Chemotherapy drugs
are notorious for causing severe gastrointestinal disruption leading to rapid weight
loss, as well as a weakened immune system that leaves individuals prone to
deadly infections (12). Despite the many treatment options to combat head and
neck cancer, treatment resistance is common and contributes to increased
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mortality. New and improved treatment options are needed to increase patient
survival and quality of life.
1.1.2 Understanding the role of oxidative stress in head and neck cancer
1.1.2.1 Origin of oxidative stress and its impact on cellular components
Oxidative stress has been implicated in the development of cancer. This is
thought to be a result of damage to key cellular components such as RNA, lipids,
proteins, and DNA (13-18). Oxidative stress occurs as a result of imbalance
between reactive oxygen species (ROS) with the antioxidant systems responsible
for ROS neutralization (19-21). These groups are composed of both radical and
non-radical compounds. Free radicals contain unpaired electrons and in an effort
to become stable, remove electrons from other molecules (22). This process leads
to the formation of additional free radicals that must be neutralized in order to
prevent further damage (22). Non-radicals do not contain unpaired electrons.
However, they can be converted into radical compounds. ROS radicals include
superoxide (O-), hydroxyl (OH), alkoxyl radical (RO), and peroxyl radical (ROO)
(22,23). Some of the non-radical ROS forms include hydrogen peroxide (H2O2),
singlet oxygen (1O2), ozone (O3), and organic peroxide (ROOH) (22,23). ROS are
generated during normal metabolic reactions due to oxidative phosphorylation in
the mitochondria (20,24). In addition, reactive oxygen species are generated in
response to exogenous sources such as ultraviolet light, ionizing radiation, and
lifestyle factors such as tobacco and alcohol usage (25).
Oxidative stress can damage critical cellular components including RNA,
proteins, lipids, and DNA, and is thought to be involved in tumorigenesis. RNA is
4

particularly prone to oxidative damage due to its close proximity to ROS created
by the mitochondria. Unlike DNA, RNA is single stranded and there are few repair
mechanisms compared to what DNA has. Damaged RNA can result in abnormal
protein synthesis, but little is known about its role in cancer (13,17,26,27).
Oxidative stress can also inactivate and induce proteolysis of proteins, including
inactivation of antioxidant proteins (28,29). This likely exacerbates levels of
oxidative stress and further increases cellular damage. Oxidative stress causes
lipid peroxidation. This can result in disruption of cellular membranes and lead to
the formation of malondialdehyde (15,30). Malondialdehyde, an active carbonyl,
creates protein and DNA adducts (15). Significantly elevated levels of
malondialdehyde been reported in head and neck cancer patients, which was
linked to increased recurrence, and reduced survival (16,31,32). Oxidative stress
can therefore damage numerous cellular components and disrupt normal cell
function.
Oxidative stress can lead to DNA damage and cause the formation of single
and double stranded DNA breaks. ROS damage the sugar-phosphate backbone
of DNA, as well as pyrimidine and purine nucleotides (23,33). There are over 20
known forms of oxidized DNA nucleotides (23,33). Guanine is the most commonly
oxidized nucleotide as it has the lowest oxidation potential of all nucleotides (34).
The most prevalent forms of oxidized guanine include 8-oxoguanine (8-oxoG), and
2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG) (20,34,35). Unrepaired
DNA damage can lead to the formation of DNA mutations in key oncogenes and
tumor suppressors, which contribute to tumorigenesis.
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1.1.3 Repair of oxidative DNA damage
Repair of oxidative DNA damage is essential in preventing tumor
development. Oxidative damage of lipids, RNA, and proteins are detrimental to the
cell, but can be more easily removed and replaced. Oxidative damage to DNA is
much more critical as DNA is the instructional foundation from which all other
cellular components are made. Mutations within key oncogenes and tumor
suppressors contribute to tumorigenesis (36,37). Therefore, it is of the utmost
importance to correct oxidative DNA damage in order to prevent the formation of
DNA mutations.
Base excision repair is largely responsible for repair of oxidative DNA
damage including the repair of damaged nucleotides, abasic sites, and single
strand breaks (Figure 1-2) (20,38-40). Damaged DNA bases are initially
recognized

by

a

family

of

enzymes

called

glycosylases

(20,38-40).

Apurinic/apyrimidic endonuclease 1 (APE1) then cleaves the phosphodiester bond
in the sugar-backbone, which generates a 3’-OH termini (20,40,41). The
deoxyribophosphodiesterase (dRpase) activity of polymerase beta creates a 5’-P
through removal of the 5’-ribose moieties (20,38). Ligation occurs as the final step
of base excision repair after polymerases fill in the break-site gap (20,40-44). Base
excision repair is important in repairing oxidative DNA damage in order to prevent
the formation of tumorigenic mutations.
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Reproduced from Scott, T.L.; Rangaswamy, S.; Wicker, C.A.; and Izumi, T.
Antioxidants & Redox Signaling. 2014. 20(4): 708-26.

Figure 1-2: Base Excision Repair
A. DNA glycosylases recognize and remove damaged DNA bases. B. This leads
to the creation of an abasic site or single strand break. C. APE1 processes 3’ ends
and creates the 3’-OH termini necessary for DNA polymerase activity. D. DNA
polymerase beta generates 5’-P termini through removal of 5’ribose moieties, and
fills in the gap. E. Finally, DNA is ligated with DNA ligase I or III.
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1.1.4 Antioxidant mechanisms to combat oxidative stress
Although there are numerous DNA repair pathways to prevent the formation
of DNA mutations, cells also have complex antioxidant systems to neutralize
oxidative stress in order to prevent damage. Superoxide anions (O-) are
neutralized by the superoxide dismutase (SOD) family (22,45,46). They do so by
dismutation of superoxide anions into oxygen and hydrogen peroxide (O-  O2 +
H2O2) (22,46,47). The hydrogen peroxide formed is relatively stable compared to
radical ROS compounds. However, it undergoes conversion to hydroxyl radicals
through Haber-Weiss or Fenton reactions, which leads to more oxidative stressinduced damage (22,23). To prevent the formation of hydroxyl radicals, hydrogen
peroxide undergoes reactions involving the enzymes catalase and glutathione
peroxidase. Catalase reduces hydrogen peroxide to water (H2O) and oxygen (O2)
(2H2O2  2 H2O + O2) (22,46). Glutathione peroxidase along with antioxidant,
glutathione (GSH), facilitates the conversion of hydrogen peroxide into water and
glutathione disulfide (GS-SG), (2GSH + H2O2  H2O + GS-SG) (46). All of the
above processes help to minimize oxidative stress and lessens its negative impact
of cellular health.
In humans, the superoxide dismutase family is comprised of 3 major
isoforms

including

SOD1

(manganese-containing

(copper,

superoxide

zinc

superoxide

dismutase),

and

dismutase),
SOD3

SOD2

(extracellular

superoxide dismutase) (46-48). Alterations of superoxide dismutases are linked to
significant pathologies including neurological and cardiac dysfunction, as well as
cancer (48-51). SOD1 is primarily located within the cytoplasm (48). While the roles
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of SOD1 in carcinogenesis have not been well clarified, alterations of SOD2 and
SOD3 have been observed in cancer (51).
SOD2 is predominantly located within mitochondria (48). SOD2 has
conflicting results as to its role in cancer (31,48,52-55). Reduction of SOD2 has
been reported in pancreatic cancers as well as in invasive breast cancers
(52,54,56). Increased cellular proliferation of pancreatic cancer cells was observed
with reduction of SOD2 (54). However, elevated SOD2 has also been reported in
gastric and lung cancer (53,55,57). In patients with gastric cancer, increased SOD2
was linked with increased lymph node metastasis, as well as reduced survival
(52,53,55).
SOD3 is associated with the extracellular matrix and is also secreted into
blood plasma and synovial fluids (36,58,59). Though primarily extracellular, there
are also reports of SOD3 localization in the cytoplasm and nucleus (60,61).
Oxidative stress induces nuclear translocation of SOD3 and this has been
proposed as a means to protect nuclear elements from oxidative stress-induced
damage (60,62,63). Secretion of SOD3 into blood plasma may be a means to
replenish cells where SOD3 has been depleted by chronic oxidative stress
(36,58,64). This seems probable, as uptake of recombinant SOD3 has been
observed in in vitro cellular studies (61,62). Superoxide dismutase activity was
reduced in the serum of head and neck cancer patients (31). This reduced
superoxide dismutase activity likely contributes to oxidative stress and cellular
damage in individuals with head and neck cancer. These studies underscore the
importance of SOD3 in the development and progression of cancer.

9

1.1.5 Field cancerization in head and neck squamous cell carcinoma
Field cancerization contributes to the development of head and neck
cancer. In 1953, Dr. Danely P. Slaughter first described the concept of field
cancerization upon observation of the existence of multifocal squamous cell
carcinoma in oral cancer. He posited this phenomenon occurs as a result of
preconditioning by unknown carcinogens for long periods of time (65). With the
discovery of DNA revealed only a few months prior to this 1953 paper, nothing was
yet known as to the genetic underlying of this occurrence (66).
Field cancerization is common in head and neck cancers, and occurs when
tissue areas are repeatedly exposed to DNA damaging agents including tobacco,
and alcohol (67,68). This chronic exposure to DNA damaging agents leads to the
formation of precancerous lesions within a field of tissue, which appears
histologically normal (Figure 1-3)(67). Due to the undetectable nature of these
lesions, precancerous fields may not be fully excised during surgery. This
remaining precancerous field can progress into secondary primary tumors.
Secondary primary tumors are not directly related to the initial primary tumor, but
may contain overlapping mutations (67-70). Criteria defines that a secondary
primary tumor have at least 2 cm of normal tissue between tumors or that the
second tumor occurs a minimum of 3 years after the initial tumor (69). In addition,
secondary field tumors that are more closely related to the initial primary tumor
may develop (Figure 1-3). This extensive and histologically normal field of
precancerous lesions are particularly problematic as it contributes to higher rates
of disease recurrence (68,69).

10

Figure 1-3: Field Cancerization
Long-term exposure of tissues to DNA damaging agents such as tobacco, alcohol,
and UV can lead to mutations in large areas of tissue forming a precancerous field.
This field appears histologically margin and can extend well beyond surgical
margins. This field can develop secondary primary tumors that are independent of
the initial primary tumor. Secondary field tumors that are independent or due to
field progression can also occur.
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Field cancerization leads to development of multifocal lesions due to
widespread exposure to DNA damaging agents (68,69). Field cancerization can
lead to a concomitant (i.e. simultaneous) existence of carcinoma in situ (CIS) and
invasive cancer(71). CIS is early stage cancer that involves only the epithelial cell
layers, whereas invasive cancer has disrupted the basement membrane (71).
Reduced recurrence free survival and overall survival were observed in patients
with concomitant CIS and invasive (Stage T1) bladder cancer (71,72). However,
concomitant CIS and invasive tumor is a little studied phenomenon in head and
neck cancer and thus it is unclear as to its clinical significance.
Several mechanisms have been proposed to explain the multifocal nature
of head and neck cancer (67,73). It has been proposed that these tumors are
monoclonal and are the result of intra-epithelia migration, or a transfer of sloughed
cancer cells (67,73). It has also been proposed that these tumors are polyclonal,
and developed more independent of one another (67,73). Either mechanism may
explain the presence of concomitant invasive tumor with CIS. Both progressive
genetic alterations that occur during intra-epithelial migration and the development
of separate closely related cancerous tissues might result in concommitant CIS
and invasive tumor within tissue fields.
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1.1.6 Head and neck cancer risk factors and their contributions to
oxidative stress
1.1.6.1 Reduction of SOD3 is associated with increased susceptibility to
tobacco induced oxidative stress
Tobacco usage increases the risk of developing cancer including lung,
pancreatic, and head and neck cancer (74,75). Tobacco combustion produces
thousands of compounds, including nearly 100 carcinogens (74-79). Tobacco
cigarettes produces free radicals that contribute to increased oxidative stress
(22,23,79). This is supported by significantly increased levels of oxidative stress
marker 8-hydroxy-2’-deoxyguanosine in smokers, and in bronchial epithelial cells
treated with cigarette smoke extract (80). As previously mentioned, oxidative
stress contributes to DNA damage. Uncorrected DNA damage can lead to
mutations in critical oncogene and tumor suppressor genes, which can promote
tumorigenesis.
Members of the cellular antioxidant system including glutathione, and
superoxide dismutases are crucial in minimizing the DNA damaging effects of the
free radicals found in cigarette smoke (81-83). Overexpression of SOD3 reduced
the levels of oxidative stress in mouse macrophages exposed to cigarette smoke
extract (84). SOD3 levels are significantly increased in individuals having the
SOD3 R213G mutation, which was associated with reduced incidence of chronic
obstructive pulmonary disease in smokers (81,82,85,86). In addition, reduction of
SOD3 was observed in lung cancer tissues as compared to matched normal
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tissues (87). These studies highlight the importance of SOD3 in reducing the
damaging effects of cigarette smoke.
1.1.6.2 Human papillomavirus infection contributes to oxidative stress
Human papillomavirus (HPV) is a growing risk factor for head and neck
cancer and is associated with increased cellular proliferation and oxidative stress.
HPV-associated oral cancers have increased 225% between 1988 and 2004 and
this is thought to be associated with changing trends in sexual behaviors (88-92).
High-risk HPV strains have been associated with several cancers including 7090% of oral cancers (88-99). Head and neck cancer development is linked to HPV
strains 16 and 18, increased sexual activity, and younger populations (6). HPV
infects and replicates viral components within epithelial layers such as oral
mucosal epithelia (100,101). High-risk strains of HPV encode viral proteins E6 and
E7, which inactivate tumor suppressors p53 and retinoblastoma (Rb) (4,100-103).
Inactivation of Rb induces overexpression of p16 (101,104). Typically, p16 inhibits
cellular proliferation. However, the inactivation of tumor suppressor and cell cycle
inhibitor Rb may override p16’s attempts in halting cellular proliferation (105,106).
Overexpression of p16 protein as determined by immunohistochemistry
(IHC), has been used as a surrogate marker for HPV infection. However, more
direct methods including HPV in situ hybridization and PCR exist and these are
often used to confirm p16 positive IHC results (4,6). There has been concern over
the accuracy of using p16 as an indirect marker for HPV infection. Shi et al.
analyzed 111 oral squamous cell carcinoma samples using IHC for p16, HPV16 in
situ hybridization, and PCR amplification of E6 mRNA. IHC results for p16 were
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significantly in agreement with HPV16 in situ hybridization, and PCR amplification
of E6 mRNA. Ninety-two percent of IHC p16 positive samples were HPV16 in situ
hybridization positive, and 86% had positive PCR amplification of E6 mRNA (107).
These results support that p16 overexpression as determined by IHC is an
accurate surrogate to identify HPV infection.
Increased oxidative stress in HPV infected tissues has been attributed to
the E6 and E7 viral proteins (25,104). Cervical cancer cells expressing E6
exhibited higher levels of ROS and 8-oxoguanine as compared to E6-negative
cells (102). Transfection of E6 into oral keratinocytes induced higher levels of 8oxoguanine, and DNA fragmentation as indicated by increased comet tail length
(102). Elevated ROS and superoxide levels were identified in HPV-positive head
and neck cancer cells as compared to HPV-negative cells (25,104). Artificial
expression of E6/E7 in HPV-negative head and neck cells led to increased levels
of ROS, and DNA fragmentation as assessed by comet assay (104). These results
support that HPV E6/E7 viral proteins promote oxidative stress and DNA damage
in infected tissues. This damage can lead to tumorigenic mutations and the
development of cancer.
Patients with HPV-associated head and neck cancers have a more
favorable prognosis, including increased survival and reduced rates of recurrence
(108). Marur et al. demonstrated that patients with HPV-associated cancers have
a 94 % [95% CI, 87-100] overall survival rate and 85 % [95% CI, 74-99] progression
free survival rate in a 2 year period (6). HPV negative tumors were linked to only
58 % [95% CI, 49-74] overall survival, and 53% [95% CI, 36-67] progression free
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survival (6). This more favorable prognosis is likely due to increased treatment
sensitivity, and earlier identification as compared to HPV-negative tumors(108).
This improved treatment sensitivity is supported by increased DNA damage in
HPV-positive head and neck cancer cells upon ionizing radiation (104). DNA
damage was identified based on increased DNA fragmentation observed by DNA
comet assay, and the presence of micronuclei (104). In addition, these studies
demonstrated correlation between increased ROS and treatment sensitivity in
HPV-associated cells and in cells where E6/E7 was artificially expressed (104).
These observations may partly explain why HPV-associated head and neck
cancers are more radiosensitive than HPV-negative tumors. Therefore, HPV is an
important risk factor for the development of head and neck cancer, and HPV’s
surrogate biomarker p16 aids in predicting treatment response.
1.1.7 Head and neck cancer development is associated with an intricate
network involving APE1
1.1.7.1 Aberrant APE1 expression is linked to increased metastasis and
treatment resistance, which contributes to reduced patient survival
As a DNA repair protein, APE1 is predominantly located within the nucleus
and mitochondria, and minimally so in the cytoplasm (20). However, aberrant
overexpression and cytoplasmic localization have been identified in cancer tissues
(109,110). This aberrant overexpression and cytoplasmic localization has been
linked to metastasis, treatment resistance, and poor patient survival (20,109-112).
APE1 overexpression may be linked to increased oxidative stress. Oxidative stress
is typical of the tumor microenvironment and previous research using mammalian
16

cell lines demonstrated that oxidative stress induces APE1 expression (19,113).
Reduced levels of antioxidants are often observed within tumor tissues (52,114).
This reduction in antioxidants may contribute to APE1 induction by through
increased oxidative stress.
Overexpression of DNA repair proteins in cancer may limit the DNA
damaging effects of chemoradiotherapy that are needed to effectively kill tumor
cells. Chemoradiotherapy is used to kill tumor cells by inducing DNA damage.
Overexpression of DNA repair proteins may therefore increase repair of DNA
damage induced by chemoradiotherapy, which may allow tumor cells to survive
treatment.
In addition to being a base excision repair protein, APE1 is also a redox
dependent transcriptional regulator (39,115-119). APE1 regulates transcription of
genes including nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB), hypoxia inducible factor 1 (HIF1), and Nuclear Factor, Erythroid 2-Like 2
(NRF2) (118). NF-kB is a prosurvival gene that is frequently upregulated in head
and neck cancers and it has been associated with both treatment resistance and
reduced patient survival (120). APE1 mediates hypoxia inducible factor 1 (HIF1)
induction(118). HIF1-mediated induction of vascular endothelial growth factor
(VEGF) leads to angiogenesis, which supports tumor growth (118). NRF2 is a
transcriptional regulator that suppresses transcription of antioxidant genes such as
SOD2 and SOD3 (121). Dr. Suganya Rangaswamy of Dr. Izumi’s lab previously
conducted microarray analysis comparing gene expression in cells with wildtype
APE1 levels and in cells deficient in APE1 (122). This previously published study
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was conducted using mouse embryonic fibroblasts that are deficient in APE1.
These fibroblasts were nullizygous for APE1, but contained a copy of the human
APE1 gene in order to maintain cell viability (122,123). Increased APE1 expression
was associated with increased levels of transcriptional co-activator, peroxisome
proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A), and
decreased levels of extracellular matrix protein, decorin (DCN) (122). Therefore,
the redox transcriptional activities of APE1 may alter transcription of key tumor
suppressor and antioxidant genes, which contributes increased tumor growth,
metastasis, and reduced survival.
1.1.7.2 Loss of decorin enhances tumor development
DCN is a small, leucine-rich proteoglycan that acts as a tumor suppressor
by preventing tumor growth and spread (124,125). Loss of DCN is associated with
increased metastasis in patients having oral squamous cell carcinoma, lung, or
breast cancer (126-132). DCN inhibits (VEGF-alpha) thereby inhibiting
angiogenesis that is needed to support tumor growth (124,132). Increased VEGFalpha protein expression, microvessel density, and lymph node involvement was
associated with low DCN protein expression within oral squamous cell carcinoma
(132). DCN also inhibits metastasis through upregulation of E-cadherin, which is
needed to maintain cell adhesion. Maintaining cell adhesion prevents the
epithelial-mesenchymal transition necessary for metastasis (120,125,126). During
epithelial-mesenchymal transition, cells return to a more stem-like state, allowing
their migration to distant sites where new tumors can form (120). This has been
supported by increased colorectal tumor development in DCN null mice, which had
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significantly reduced E-Cadherin (120,125,133). Therefore, DCN is important in
suppressing tumor development.
1.1.7.3 PPARGC1A supports tumorigenesis and metastasis
PPARGC1A is a transcriptional co-activator linked to mitochondrial
biogenesis, oxidative phosphorylation, and has been implicated in tumorigenesis
(134,135). The role of PPARGC1A in supporting tumorigenesis has been
supported in Bhalla et al., which observed increased development of colon cancer
in wildtype mice as compared to their PPARGC1A knockout counterparts (135).
They also observed reduced tumor volume in mice injected with colon cancer cells
that had PPARGC1A knockdown (135). Other studies in lung adenocarcinoma and
oral squamous cell carcinoma have reported a paradoxical reduction of
PPARGC1A in invasive tissues as compared to matched normal samples
(134,136). LeBleu et al. discovered that PPARGC1A gene expression is increased
in circulating cancer cells as compared to primary and metastatic tumors. They
demonstrated that PPARGC1A knockdown inhibited metastasis without impacting
cell proliferation within the primary tumor (137). Taken together, these studies
support that increased PPARGC1A supports tumorigenesis and metastasis.
1.1.7.4 NRF2 suppresses key antioxidant genes
Nuclear Factor, Erythroid 2-Like 2 (NRF2) is a transcriptional regulator of
antioxidant and cell proliferation genes (138,139). APE1 is a proposed NRF2
regulatory protein (140-142). This regulatory link is supported with the observation
of reduced NRF2 in cardiac tissue where APE1 was knocked down (140). In this
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same study, physical interaction of NRF2 and APE1 was demonstrated in
immunoprecipitation experiments (140). Increased NRF2-mediated transcription
has been observed upon APE1’s interaction with NRF2 (141). This would support
that APE1 may not only increase NRF2 expression, but also NRF2 activity. In
contradiction, one study observed a negative regulatory link between APE1 and
NRF2. Knockdown experiments performed in pancreatic cancer cell lines
demonstrated increased NRF2 expression, as well as increased expression of
NRF2 downstream targets (142). It should be noted that these experiments were
performed in various pancreatic cancer cell lines, and there might be some form
of cell type specific regulation. APE1 and NRF2 are both upregulated in HNSCC
(143-146). Therefore, it is likely that a positive regulatory link between APE1 and
NRF2 exists in head and neck tissues.
As mentioned, NRF2 is an important regulator of antioxidant genes. SOD2, SOD3,
and DCN gene downregulation was reported in type II alveolar cells with wildtype
NRF2 as compared to their homozygous NRF2 knockout counterparts (121).
Suppression of SOD2 protein was also observed in the skeletal muscle of aged
wildtype mice as compared to the NRF2 homozygous knockout mice (147). In
addition, NFE2L2 transcription factor binding sites were identified in the DCN and
SOD3 promoter regions (Table 1-1)(148-150). Therefore, increased NRF2
expression and activity in HNSCC may increase suppression of superoxide
dismutases leading to increased oxidative stress.
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Table 1-1: NFE2L2 transcription factor binding sites within the DCN, and
SOD3 promoter regions

NFE2L2 (MA0150.1) transcription factor binding sites were determined using
LASAGNA-Search 2.0 with matrix-derived JASPER CORE models. NFE2L2
consensus logo obtained from JASPER.
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1.2

Experimental Rationale
A major challenge concerning HNSCC is how to overcome treatment

resistance and recurrence, which eventually leads to reduced patient survival
(151). APE1 overexpression in tumors has been associated with metastasis,
treatment resistance, and reduced patient survival (20,109-112). However, the
mechanisms underlying this remain unclear. Previous microarray experiments
suggest that APE1 significantly reduces gene expression of DCN (122). Reduced
DCN expression has been associated with increased metastasis and mortality in
cancer patients (126-132). The increased metastasis in patients with APE1
overexpression may be due to APE1 suppressing DCN levels. To explore how
APE1 may be suppressing DCN, we looked at APE1’s role as a redox dependent
transcriptional regulator.
There are studies supporting that APE1 can increase NRF2’s protein
expression and transcriptional regulatory activity (140,141). Reddy et al. previously
reported downregulation of DCN in NRF2 expressing cell lines (121). These
observations warrant to test whether suppression of DCN by APE1 occurs
indirectly through NRF2. In addition, NRF2 is linked to suppression of antioxidants
SOD2, and SOD3 (121). PPARGC1A is a known co-activator of NRF2 and
microarray analysis supports that APE1 positively regulates PPARGC1A gene
expression (122). PPARGC1A as an NRF2 coactivator may support SOD2
suppression by NRF2. However, there is evidence that PPARGC1A is a positive
regulator of SOD2 (152). Therefore, we decided to clarify the regulatory link
between PPARGC1A and SOD2.
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Chapter 1 will explore the hypothesis that APE1 expression downregulates
tumor suppressor and antioxidant proteins and in doing so contributes to increased
tumor development (Figure 1-4). We aim to gain insight into how APE1 influences
survival, and also to identify potential biomarkers that aid in predicting aggressive
tumor phenotypes, and survival. To test the proposed model, I measured protein
expression of APE1, DCN, NRF2, SOD3 and PPARGC1A within HNSCC samples
obtained from patients treated at the University of Kentucky. Digital slide image
analysis was used to measure protein expression in benign, CIS, and invasive
tissue subtypes based on immunohistochemistry staining intensity. To further
support our proposed model, gene correlation analysis was performed using
transcriptome data obtained from TCGA.
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Figure 1-4: Proposed Mechanism for APE1's role in HNSCC
I hypothesize that oxidative stress in the tumor microenvironment increases APE1
levels. APE1 interacting with NRF2 drives suppression of DCN. NRF2 also leads
to downregulation of SOD3. APE1 influences PPARGC1A driving SOD2
suppression. Downregulation of antioxidants SOD2 and SOD3 further elevates
oxidative stress driving further APE1 overexpression.
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I performed analysis to identify potential biomarkers that could predict
patient survival and aggressive tumor phenotypes including increased metastatic
potential. Kaplan-Meier survival analysis was performed where we compared
differences in protein and gene expression levels. To understand how alterations
of these proteins contributed to reduced patient survival, differences in protein
expression were analyzed in relation to various clinical factors such as the
presence of lymph node invasion, p16 status, and tumor grade. Understanding
how APE1 overexpression contributes to increased cancer mortality could lead to
the development of new and improved treatment strategies. Biomarkers that
identify high-risk patients, particularly at early stages of tumor development, can
potentially improve patient survival. I will discuss in depth some of the major
limitations of the experiments in chapter 1 as well as ways to improve this in the
future.
Chapters 2 and 3 are previously published first-author and co-first author
manuscripts respectively (116,153). In chapter 2, we analyzed normal and cancer
tissues to identify changes in genetic coordination between COP9 signalosome
components and with components of the respiratory chain complex (153). Chapter
3 discusses post-translational modification of APE1 by tumor suppressor Parkin
(116). The last chapter will summarize the findings and significance of chapters 1,
2, and 3. In addition, I discuss possible future directions to further develop the
conclusions of this study.
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1.3

Methods

1.3.1 Chemicals and other reagents
Antibodies used for this study include anti-APE1 (Santa Cruz, sc-55498),
anti-DCN (Santa Cruz, sc-22753), anti-PGC1-alpha (Santa Cruz, sc-13067), antiSOD3 (Santa Cruz, sc-67088), and anti-NRF2 (ABcam, AB31163). Our lab has
previously used Western blotting to confirm the specificity of the anti-APE1, antiDCN, anti-PGC1-alpha, and anti-SOD3 antibodies. Also utilized were anti-Ki67
(Dako IR626) and anti-desmin (Dako IR606). The Markey Cancer Center
Biospecimen and Tissue Procurement Shared Resource Facility (BSTP SRF) has
validated all antibodies listed above.
1.3.2 Head and neck squamous cell tissues and clinical data sets
Head and neck squamous cell tissue samples and de-identified clinical data
were obtained from 77 patients at the University of Kentucky’s Markey Cancer
Center following IRB guidelines. Tissue specimens were obtained from the BSTP
SRF.
Clinical data associated with these tissues were obtained from the Kentucky
Cancer Registry with the help of Dr. Eric Durbin. Clinical data sets included
information regarding patient age at diagnosis, tobacco usage, p16 status, time of
survival, pathology and clinical staging, histology, tumor grade, presence of lymph
node invasion, and whether the patient originated from the central or Appalachian
region of Kentucky.
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1.3.3 Immunohistochemistry for Head and Neck Squamous Cell Tissues
Formaldehyde-fixed paraffin embedded head and neck squamous cell
carcinoma

samples

obtained

from

the

BSTP

SRF

were

used

for

immunohistochemistry. All samples were obtained prior to the patients starting
chemoradiotherapy. Dana Napier of the BSTP SRF performed slide sectioning,
and immunostaining.
Tissue sections with 5-μm thickness were deparaffinized and rehydrated
step-wise through decreasing concentrations of ethanol and finally water. Antigen
retrieval was performed using a Biocare Medical decloaking chamber and Dako
antigen retrieval buffer. Following washing with TBS-Tween, endogenous
peroxidase activity was quenched using the Dako peroxidase-blocking reagent.
Slides were washed again in TBS-Tween and incubated with primary antibodies at
room temperature. Slides were then incubated with polymer linked secondary
antibody, either mouse (Dako K4007) or rabbit (Dako K4003). Diaminobenzidine
was used for 1-10 minutes to produce color. Slides were subsequently
counterstained with Meyer’s hematoxylin, and ammonia was used to blue slides.
Slides were dehydrated stepwise through increasing concentrations of ethanol and
cleared with xylene before coverslip fixation.
1.3.4 High-resolution digitization of Immunohistochemistry Slides
High-resolution digital image scans of our slides were obtained using the
Aperio Scanscope XT (Leica) located in the Markesbery Neuropathology lab of the
Sanders-Brown Center on Aging. Slides were scanned at 20X magnification with
a resolution of 0.5 micrometer/pixel, which is equivalent to 50,000 pixels per inch
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(approximately 4 Giga Byte per slide). Immunohistochemistry staining was
quantified using the Aperio ImageScope software (V 11.2.0.780) (154-156).
Nuclear algorithm V9 was used to determine percentage of positively stained
nuclei and calculated using the following formula [% total positive nuclei=(number
of positive nuclei/total nuclei)*100%]. Total cellular staining was determined using
the Positive Pixel Count algorithm V9 and calculated using the following formula
[% total cellular staining=(number of positive pixels/total pixels)*100].
Dr. Yolanda Brill of the University of Kentucky’s Pathology department
visually inspected hematoxylin and eosin stained slides and annotated regions of
benign, carcinoma in situ, and invasive tumor regions within slide sections. Areas
from these marked locations were then selected for analysis with the Aperio
ImageScope software.
1.3.5 Immunohistochemistry staining controls
Dr.

Brill

with

the

assistance

of

Dana

Napier

examined

the

immunohistochemistry test slides to identify the staining conditions necessary to
minimize background staining. Factors considered included antibody dilutions,
incubation periods, as well as the pH of the epitope retrieval buffer.
The accuracy of the Aperio algorithms was assessed by measuring the
staining of Ki-67 and desmin, which are known to be predominantly located within
the nuclei and cytoplasm, respectively (Supplemental Figure C-1). Test slides
probed with either Ki-67 or desmin antibodies were assessed with both the nuclear
algorithm V9 and the positive pixel algorithm V9.
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1.3.6 Pearson correlation coefficient analysis
Pearson correlation coefficient (r) analyses was performed using SPSS 23
with significance determined as p < 0.05 (2-tailed). Pearson correlation coefficients
are used to determine whether a positive or negative correlation between two
factors exists. A positive correlation indicates that as one factor increases so does
the second. A negative correlation indicates that as one factor increases, the other
decreases. Data from 77 patients initially treated at the University of Kentucky were
used to compare nuclear and total protein expression for individual proteins (for
example APE1, SOD3) and between benign, carcinoma in situ, and invasive tissue
subtypes.
1.3.7 Univariate and multivariate analysis of protein expression data
Both SAS and SPSS 23 statistical packages were used for statistical
analysis. Dr. Li Chen of the Biostatistics and Bioinformatics Shared Resource
Facility was instrumental in the univariate and multivariate statistical analysis.
Initially, univariate mixed procedure was used to determine significance of protein
changes across all 77 patient samples without regards to clinical data. Box and
whisker graphs were generated with bars representing interquartile range, internal
line representing the median, and whiskers representing the 95% CI. Multivariate
mixed procedure was used to identify significant protein changes in respective
clinical groups. Clinical data for the following were analyzed: p16 status, whether
patients were from Appalachian Kentucky, tobacco usage, age at diagnosis,
pathology stage, tumor grade, and presence of cancer infiltrated lymph nodes at
the time of diagnosis. Overall p-values were generated based on linear mixed
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models with tissue and each variable as covariates, and with compound symmetric
covariance structure. Significance was determined as p<0.005 after adjusting for
examining 10 markers simultaneously, and p<0.05 without adjusting for examining
10 markers simultaneously. Categories where significance of the overall p-value
was obtained were subjected to further analysis to determine significance of the
variable effect (example benign, CIS, and invasive). Data were plotted with error
bars representing standard error.
1.3.8 Survival analysis
The data from 77 different patients was used for survival analysis using
protein expression data under Dr. Chen’s supervision. Days of survival were
determined as days between date of diagnosis and date of death, which was then
converted to months of survival.
In order to perform Kaplan-Meier survival analysis, we first identified cutoff
values for the proposed biomarkers based on previous research from other
researchers (157,158). Cutoffs were determined for nuclear and total cellular levels
for each individual protein and within each tissue subtype (example benign, CIS,
and invasive). The quartiles of each biomarker were determined with low
expression defined as the first quartile (Q1), and high expression defined as the
third quartile (Q3).
Survival curves based on the Kaplan-Meier estimator were generated in R
3,3,1 GUI 1.68 Mavericks build 7238 (159). Additionally, xlsxjars, and rJava
packages were used to import and generate the excel files needed for survival
analysis (160-162). Survival, graphics and grDevices packages were used for
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generation of Kaplan-Meier graphs (159,163). Log Rank (Mantel-Haenszel), and
Peto & Peto modification of the Gehan-Wilcoxon test, were used to determine
statistical significance (p<0.05) (159). The Log Rank statistical test is sensitive in
detecting differences in survival for long periods of time whereas the Wilcoxon test
is better suited to detect differences at earlier time points (164).
1.3.9 HNSCC gene expression analysis
The Cancer Genome Atlas’s online data portal was used to acquire gene
expression data (mRNASe12, level3) and de-identified clinical data (example
survival time, pathology stage, anatomical location) from 520 patients having head
and neck squamous cell carcinoma (https://cancergenome.nih.gov). Gene
expression and clinical data were initially organized with programs using command
line applications developed with Swift (Xcode ver. 6) (153). Genes of interest were
further isolated from the original data set of 15,857 different genes.
Gene expression data was utilized for correlation and survival analysis.
Gene correlation was determined using TCGA RNA-Seq data from 43 matched
non-neoplastic and HNSCC tissue. This data set was used to calculate Pearson
correlation coefficients between individual genes (example APEX1, SOD3). For
survival analysis based on gene expression, patient survival was compared
between low expression (Q1) and high expression (Q3) of our genes of interest.
Cutoff values were determined using same method as with protein expression.
There were 44 patients in both low and high gene expression groups.
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1.4

Results

1.4.1 Differential protein and gene expression analysis in HNSCC
In this study we examined whether and how APE1, DCN, PPARGC1A,
SOD3, and NRF2 expression coordinated with one another, and how expression
changed between non-neoplastic and HNSCC tissues. Analysis included gene
expression analysis of data obtained from TCGA, and protein expression analysis
based on IHC staining of HNSCC obtained from the University of Kentucky. TCGA
database contains a large quantity of RNA-Seq data for HNSCC samples,
approximately 10% of which have data from matched non-neoplastic tissues (153).
Our lab previously reported the use of TCGA’s transcriptome database in the
discovery of discoordinated gene expression of COP9 subunits with mitochondriarelated genes in cancerous tissues as compared to non-neoplastic tissue (Chapter
2) (153). We applied the same methods to analyze expression of genes for APE1,
DCN, PPARGC1A, SOD2, SOD3, and NRF2 changes in non-neoplastic and
HNSCC tumor tissues. APE1 gene name is designated APEX1 and NRF2 gene
name is designated NFE2L2. To investigate gene coordination, Pearson
correlation coefficients were calculated between genes of interest in nonneoplastic and tumor tissues.
Because gene expression does not always directly correlate to protein
expression, we examined protein levels of APE1, DCN, NRF2, SOD3, and
PPARGC1A. To do so, we analyzed protein levels in tissue specimens from 77
patients treated at the University of Kentucky’s Markey Cancer Center. To
objectively measure IHC staining, we utilized digital slide image analysis using the
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Aperio ImageScope software. This software was used to calculate total cellular
and nuclear protein expression within benign, CIS, and invasive HNSCC.
Importantly, a pathologist who specializes in head and neck cancer independently
identified regions of benign, CIS, and invasive HNSCC. This helped ensure that
regions were accurately analyzed, and minimized bias in selecting regions of
analysis using the Aperio ImageScope software. Data from the protein expression
levels in proximal benign, CIS and invasive tissue were converted into box and
whisker plots. Bars represent the interquartile range, and whiskers represent the
95% confidence intervals. To determine coordination between proteins and within
each tissue type, Pearson correlation coefficients were generated.
1.4.1.1 APE1 protein expression is upregulated in CIS, and invasive
HNSCC
We first examined if APE1 expression increases in HNSCC, in order to
confirm previous studies that demonstrated APE1 overexpression in tumor tissues
(109,110,165). APE1 protein expression in benign, CIS, and invasive HNSCC was
determined using digital image analysis of IHC staining. Protein expression
analysis revealed significantly increased total cellular APE1 in CIS, and invasive
tissues as compared to benign (p<0.001 for both). In addition, APE1 protein
expression was significantly increased in invasive tissue as compared to CIS
(p<0.05). Nuclear APE1 protein expression was also elevated in both CIS and
invasive HNSCC (p<0.001, p= 0.0023 respectively) (Figure 1-6). This confirms
prior research that demonstrated increased APE1 in cancer tissues (109,110,165).
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However, to the best of our knowledge this is the first study to observed increased
APE1 protein expression in not only invasive HNSCC but also in CIS.
1.4.1.2 APE1 protein expression is linked to reduced DCN protein levels in
HNSCC
Based on our previous gene expression profiling using the wild-type and
APE1-knockdown mouse embryonic fibroblasts described in the introduction and
in Suganya et al. 2015 (122), we hypothesized that elevated APE1 leads to
reduced DCN expression in HNSCC (Figure 1-4). To determine whether APE1
expression corresponds to DCN suppression, we performed correlation analysis
at both protein and gene expression levels. Total and nuclear DCN protein levels
were determined in benign, CIS, and invasive HNSCC using digital image analysis
of IHC staining. Total and nuclear DCN protein levels were significantly decreased
in both CIS and invasive HNSCC as compared to benign tissue (p<0.001 for all)
(Figure 1-5, Figure 1-6). APE1 protein expression corresponded to significantly
decreased DCN protein expression in CIS (p<0.01) (Table 1-3). Unexpectedly,
there was a positive correlation between total cellular APE1 and DCN protein levels
in benign tissue. It is not clear as to why, but these results support dysregulation
between APE1 and DCN expression in tumor tissues.
We hypothesized that the reduction of DCN expression was a result of
APE1’s redox transcriptional regulatory activity. To examine whether APE1 gene
expression corresponded to decreased DCN gene expression, we calculated
Pearson correlation coefficients using RNA-Seq data obtained from TCGA. Gene
expression analysis revealed no significant link between APE1 and DCN (Table 1-
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2). This was unexpected as previously published microarray analysis in MEF cell
lines exhibited significantly reduced DCN gene expression in mouse embryonic
fibroblasts with wildtype APE1 as compared to cells with APE1 knockdown (122).
This difference may be due to heterogeneity of tissues versus an immortalized,
monoculture cell line. Further work is needed to determine whether APE1 impacts
DCN gene regulation.
1.4.1.3 APE1 protein levels are linked to increased NRF2 protein levels
We hypothesized that APE1 indirectly downregulates DCN and SOD3 by
modulating NRF2’s transcriptional regulatory activity (Figure 1-3). APE1 is known
to regulate NRF2 expression as well as increase NRF2’s transcriptional regulatory
activities (140,141). We first determined overall changes of NRF2 protein
expression in benign, CIS, and invasive HNSCC using digital image analysis of
IHC slides. Total cellular NRF2 protein levels were increased in invasive HNSCC
as compared to benign tissue (p<0.05) and to CIS (p=0.0002) (Figure 1-6). Gene
expression coordination was investigated between NFE2L2, DCN, SOD2, and
SOD3. To examine this coordination, we calculated Pearson correlation
coefficients in non-neoplastic and tumor tissues using TCGA RNA-Seq data from
patients with HNSCC. In non-neoplastic tissues, NFE2L2 gene expression was
negatively correlated with DCN, SOD2, and SOD3 (p<0.01) (Table 1-2). This
supports that NRF2 may negatively regulate transcription of DCN, SOD2, and
SOD3. Additionally, we analyzed coordination between protein levels of NRF2,
DCN, and SOD3. Overall, there was a trend toward negative correlation between
nuclear NRF2 and DCN protein levels. However, NRF2 protein had a positive
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correlation with nuclear DCN and SOD3 in invasive tissues (p<0.05). Overall,
these results support that NRF2 may be involved in suppressing transcription of
SOD2, SOD3, and DCN.
Next, we explored coordination between NRF2 and APE1 protein
expression in benign, CIS, and invasive HNSCC by calculating Pearson correlation
coefficients. Investigation of protein expression demonstrated a positive
correlation between nuclear APE1 and NRF2 in benign (p<0.01) and invasive
tissue (p<0.01) (Table 1-3 A). Additionally, a positive correlation was found
between nuclear APE1 protein levels in benign tissue and nuclear NRF2 protein
levels in CIS (p<0.05) (Table 1-3 A). These results signify that increased APE1
protein expression in benign and invasive tissue corresponds to increased NRF2
protein expression in benign and invasive tissues. These initial results supported
that APE1 may positively regulate NRF2 levels in HNSCC.
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Figure 1-5: Representative images of Hematoxylin and Eosin, and IHC for APE1, DCN, NRF2, SOD3, and PPARGC1A
in benign, carcinoma in situ, and invasive HNSCC
Digital image scans of benign, carcinoma in situ, and invasive HNSCC from a single patient. Serial sections were used for
hematoxylin and eosin (H&E) staining, and immunohistochemistry staining to detect APE1, DCN, SOD3, NRF2, and
PPARGC1A.
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Figure 1-6: Quantification of Total Cellular and Nuclear APE1, DCN, NRF2, SOD3, and PPARGC1A in benign,
carcinoma in situ, and invasive HNSCC

Immunohistochemistry staining was analyzed with Aperio software to determine protein levels of APE1, DCN, NRF2, SOD3,
and PPARGC1A in benign, CIS, and invasive HNSCC. Bars represent the interquartile range and whiskers represent the
95% confidence intervals. Data is representative of 77 patients.
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Table 1-2: Correlation of TCGA HNSCC gene expression

RNA-Seq data from 43 matched non-neoplastic and HNSCC samples was
obtained from TCGA. Pearson correlation coefficients were generated from this
data to examine gene coordination between APEX1, DCN, SOD2, SOD3, NFE2L2,
and PPARGC1A in non-neoplastic and HNSCC tumor tissues. ** Correlation is
significant p<0.01 (2-tailed). *Correlation is significant p<0.05 (2-tailed).
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Because gene expression analysis revealed no correlation between
NFE2L2 and APEX1, the positive correlation observed between APE1 and NRF2
protein expression may not be due to increased gene expression of NRF2 (Table
1-2, 1-3). These results do not discount the possibilty of increased NRF2 activity
through interaction with APE1, which has been observed in other systems (141).
Future in vitro studies will be needed to confirm whether APE1 is increasing NRF2
activity. Determining if APE1 increases NRF2 activity in head and neck cancer is
necessary to understand how APE1 suppresses DCN and SOD3 in tumor tissues.
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Table 1-3: Pearson correlation analysis for APE1 and associated Factors in benign, CIS, and invasive HNSCC
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Table 1-3: Pearson correlation analysis for APE1 and associated factors in benign, CIS, and invasive HNSCC (Cont.)
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Table 1-3: Pearson correlation analysis for APE1 and associated factors in benign, CIS, and invasive HNSCC (Cont.)
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1.4.1.4 Suppression of superoxide dismutase upon increased APE1
expression
We hypothesized that APE1 drives SOD3 suppression in HNSCC (Figure
1-4). We first determined whether SOD3 decreases in HNSCC in benign, CIS, and
invasive HNSCC by using digital image analysis of IHC slides. Both total and
nuclear SOD3 protein levels were decreased in CIS and invasive tissues as
compared to benign tissues (p<0.0001). SOD3 protein levels were additionally
reduced in invasive HNSCC as compared to CIS (p<0.05) (Figure 1-6)
We next investigated correlation between APE1 and SOD3 protein levels in
benign, CIS, and invasive HNSCC. Correlation between proteins was determined
by calculating Pearson correlation coefficients. There was an overall trend of
negative correlation between APE1 and SOD3 protein levels in tissue subtypes. A
significant negative correlation was observed between total APE1 protein in benign
tissue with total SOD3 protein in CIS (p<0.05) (Table 1-3 C). Additionally, there
was a significant negative correlation between total APE1 and nuclear SOD3
protein in benign tissue (p<0.05) (Table 1-3 B). Gene coordination between
APEX1 and SOD3 had an overall negative trend. In non-neoplastic tissues, there
was a slight negative correlation observed between APEX1 and SOD3 (p=0.09)
(Table 1-2). There was also a negative correlation between APEX1 and SOD2
gene expression in non-neoplastic tissue (p=0.059) (Table 1-2). This data partially
supports that APE1 is involved in suppression of antioxidants SOD2 and SOD3.
Larger data sets need to be analyzed to determine if there is a statistically
significant reduction of SOD3 gene expression in tissues with elevated APE1. This
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is important, as oxidative stress is known to induce APE1 expression. APE1
suppressing superoxide dismutases and subsequent increased oxidative stress
may further drive APE1 overexpression in tumor tissues.
1.4.1.5 APE1 is positively linked to PPARGC1A gene and protein
expression
We examined whether APE1 is linked to altered PPARGC1A expression in
HNSCC because our lab previously identified increased PPARGC1A expression
in MEF cells with wildtype APE1 expression (122). First, we examined total cellular
and nuclear PPARGC1A protein levels in benign, CIS, and invasive HNSCC using
digital image analysis of IHC staining. We observed a significant decrease in
nuclear PPARGC1A protein in cancerous tissues (p<0.001 benign versus invasive,
p<0.05 benign versus CIS) (Figure 1-6). This reduction of PPARGC1A in tumor
tissues supports previous research, which demonstrated loss of PPARGC1A
protein in invasive tumor as compared to benign tissue (137).
We next calculated Pearson correlation coefficients to investigate
coordination between APE1 and PPARGC1A protein levels. There was a
significant positive correlation of nuclear APE1 protein in invasive with nuclear
PPARGC1A protein in both benign and invasive tissue (p<0.05) (Figure 1-6). A
positive correlation was also observed between APE1 protein in CIS and
PPARGC1A protein in benign tissue (Table 1-3). These results support a positive
correlation between APE1 and PPARGC1A protein levels. Next, we investigated
whether there was also a positive correlation between APEX1 and PPARGC1A
gene expression. There was a significant positive correlation between APEX1 and
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PPARGC1A gene expression in tumor tissue (p<0.05), but not in non-neoplastic
tissues (Table 1-2). This suggests that APEX1 and PPARGC1A gene coordination
becomes altered in cancerous cells. This positive correlation supports previous
work performed in MEF cells (122).
1.4.1.6 NRF2 gene expression is linked to reduced gene expression of
DCN, SOD2, SOD3
We hypothesized that NRF2 mediated transcriptional downregulation of
DCN, SOD2, and SOD3 (Figure 1-3). Gene expression coordination was
investigated between NFE2L2, DCN, SOD2, and SOD3. To examine this
coordination, we calculated Pearson correlation coefficients in non-neoplastic and
tumor tissues using TCGA RNA-Seq data from patients with HNSCC. In nonneoplastic tissues, NFE2L2 gene expression was negatively correlated with DCN,
SOD2, and SOD3 (p<0.01) (Table 1-2). This supports that NFE2L2 may negatively
regulate transcription of DCN, SOD2, and SOD3. Additionally, we analyzed
coordination between protein levels of NRF2, DCN, and SOD3. Overall, there was
a trend toward negative correlation between nuclear NRF2 and DCN protein levels.
However, there was a positive correlation between nuclear NRF2 and nuclear DCN
protein levels in invasive tissue (p<0.05 (Table 1-3 A). In addition, there was a
positive correlation between nuclear NRF2 and nuclear SOD3 in invasive tissue
(Table 1-3 A).
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1.4.2 Survival Time in relation to APE1, DCN, NRF2, SOD3, and
PPARGC1A expression
Biomarkers that predict patient survival may provide insight into novel drug
targets, which could lead to improved therapeutics and increased patient survival.
Therefore, we investigated whether APE1, DCN, NRF2, SOD3, or PPARGC1A
expression could predict patient survival. To do this we performed Kaplan-Meier
survival analysis using the protein expression data obtained from 77 patients with
HNSCC. We first calculated the quartiles for each protein and within each tissue
subtype. Survival was then compared between low protein expression (Q1) and
high protein expression (Q3). We next examined survival of patients with stage
T4a HNSCC with regards to APEX1, DCN, NFE2L2, SOD3, and PPARGC1A gene
expression using TCGA RNA-Seq data. We then compared patient survival
between low protein expression (Q1) and high protein expression (Q3).
1.4.2.1 Patients with elevated APE1, and PPARGC1A expression had
significantly shorter survival periods
Previous research has observed reduced survival in patients whose tumors
had aberrant APE1 expression (20,109-112). To confirm that reduced survival is
associated with elevated APE1 levels, we created Kaplan-Meier survival plots for
total cellular and nuclear APE1 protein expression in benign, CIS, and Invasive
tissues. In CIS, increased total cellular APE1 protein was linked to decreased
survival (LR p<0.05, GW p<0.05) (Figure 1-7). To the best of our knowledge, this
is the first study where high APE1 protein expression in CIS was linked to
decreased patient survival. We next determined whether elevated APE1 gene
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expression was associated with reduced survival, as we had found with protein
expression. Gene expression analysis using TCGA data for HNSCC (pathology
stage T4a) also revealed reduced survival in patients with elevated APE1 (LR
p= 0.0148, GW p= 0.0101) (Figure 1-8). Patients with high total PPARGC1A in
invasive tissue had significantly reduced survival (LR p<0.05, GW p= 0.0575)
(Figure 1-7).
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Figure 1-7: Top significant survival curves based on protein expression
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Kaplan Meier survival curves were generated comparing low protein expression
(Q1) versus high protein expression (Q3) in the samples of deceased patients.
These graphs represent the top significant results as determined by LR: MantelHaenszel Log-Rank, GW: Peto & Peto modification of the Gehan-Wilcoxon
statistical tests (p<0.05). A: % Total Cellular APE1 protein expression in CIS B.
% Nuclear DCN Protein Expression in benign tissue C. % Total Cellular
PPARGC1A protein expression in invasive tissue.
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Figure 1-8: APEX1 gene expression survivals analysis

RNA-Seq data from 520 patient samples were used to generate Kaplan Meier
survival curves. Differences in survival were determined between individuals with
low APE1 gene expression (Q1) versus high APE1 gene expression (Q3).
Statistical significance was determined using LR: Mantel-Haenszel Log-Rank, and
GW: Peto & Peto modification of the Gehan-Wilcoxon statistical tests.
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1.4.2.2 DCN protein levels in benign tissue is linked to reduced survival
We analyzed DCN protein expression to confirm previous reports that
reduced DCN was linked to poor survival (126-132). To do so, we plotted KaplanMeier survival curves for total cellular, and nuclear DCN protein levels in each of
the tissue subtypes. There appeared to be reduced survival in patients with low
DCN expression in CIS. However, there were too few events (i.e. patient deaths)
to obtain a statistically significant result. We suspect that low DCN protein
expression in CIS corresponds to reduced survival, but a larger data set will be
needed to confirm the link between low DCN protein levels and reduced survival.
Unexpectedly, overexpression of DCN in benign tissue was linked to poor survival
(LR p=0.0493)(Figure 1-7).
1.4.3 Multivariate analysis of protein expression within clinical groupings
Clinical data from the patients whose samples were used for protein
expression analysis were obtained from the Kentucky Cancer Registry. Major
categories examined were p16 status, whether patients were from Appalachia
Kentucky, tobacco usage, tumor grade, presence of cancer positive lymph nodes,
age at diagnosis, tumor size, pathology stage, and location of primary tumor (Table
1-4). Initially, overall p-values were calculated to identify significant differences of
each protein within clinical groups (Table 1-5). For clinical factors that were found
to have significant overall p-values, additional statistical analysis was performed
to identify if there was significant difference at the variable effect (i.e. benign, CIS,
invasive). There were no significant differences of APE1, DCN, NRF2, SOD3, or
PPARGC1A regarding location of the primary tumor, tumor size, whether a patient
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was from Appalachia Kentucky, or upon comparing patients having pathology
stage 2/3 versus stage IV (Table 1-5).
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Table 1-4: Patient Demographics

Table represents demographics of the 77 patients whose samples were utilized for
immunohistochemistry
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Table 1-5: Overall P values for clinical analysis

Values represent overall P-value for clinical analysis of patient P16 status, patient
geographic location, tobacco usage, tumor grade, lymph node invasion, age at
diagnosis, tumor size, pathology stage, and primary site location. These results
were based on linear mixed models with tissue type and each variable as
covariates and with compound symmetric covariance structure. They represent the
overall p values for association of each variable across each biomarker and across
benign, CIS, and invasive tissue. ** p<0.005 denotes significance after adjusting
for examining 10 markers simultaneously. * p<0.05 denotes significance without
adjusting for examining 10 markers simultaneously.
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1.4.3.1 Elevated APE1 was associated with cancer invaded lymph nodes
It is estimated that at least 90% of cancer-related deaths are a direct result
of metastasis (166). During metastasis, cancer cells break away from the primary
tumor and spread throughout the body (166). This leads to compromised functions
of vital organs, eventually leading to death. A biomarker that identifies increased
risk for metastasis could improve patient survival by allowing physicians to tailor
the aggressiveness of treatment, or increase surveillance in order to identify
metastasis sooner.
To identify a potential biomarker for increased risk for metastasis, we
examined whether altered expression of our proteins of interest corresponded to
the presence of cancer within a patient’s lymph nodes. Given that metastatic cells
originate from the primary tumor, we compared protein expression changes in the
primary tumors of patients who had lymph node invasion at the time of diagnosis
to those that did not. Out of the cohort of 77 patients, 13.0% had no lymph nodes
that were positive for cancer (n=10), and 16.9 % had 1 or more cancer positive
lymph nodes (n=13). Excluded from analysis were individuals whose lymph nodes
were not assessed at the time of sample collection (n=54)(Table 1-4). Biomarkers
that predict aggressive phenotypes (i.e. lymph node invasion) would be most
useful if identified in early tumor development, such as in CIS. To determine if
alterations in CIS could be linked to the presence of lymph node invasion, we
examined alterations in protein expression. There were significantly higher levels
of both total and nuclear APE1 in CIS in patients that had lymph node invasion at
the time of diagnosis (p<0.05) (Figure 1-9).
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Figure 1-9: Analysis of protein expression and presence of lymph node invasion at diagnosis.
Nuclear and total cellular APE1, DCN, SOD3, NRF2, and PPARGC1A protein levels were determined in benign, CIS, and
invasive HNSCC within the primary tumor. Values were compared between 10 patients with no lymph node invasion to 13
patients that had lymph node invasion at the time of diagnosis. * Denotes statistical significance (p<0.05).

1.4.3.2 Altered expression of DCN, SOD3, AND PPARGC1A in patients with
poorly differentiated tumors
Tumor grade (i.e. the level of cellular differentiation) also influences
prognosis.

Tumor

tissues

vary

between

well

differentiated,

moderately

differentiated and poorly differentiated. Well-differentiated tumors most closely
resemble normal tissue, whereas poorly differentiated tumors are more stem-like
(167). The latter of which is associated with poor patient survival. Our goal was to
determine if altered expression of APE1, DCN, SOD3, NRF2, and PPARGC1A
could identify patient prognosis, or understand how altered expression of these
proteins influence tumor grade. Out of the cohort of 77 patients, 37.7 % had poorly
differentiated tumors (n= 29), and 32.5 % had moderately differentiated tumors
(n=25). Excluded from analysis were individuals with unknown tumor grade (n=22)
and an individual with a well-differentiated tumor (n=1)(Table 1-4). Benign tissue
and CIS proximal to the invasive HNSCC were analyzed for protein expression as
measured by immunohistochemistry staining intensity.
DCN protein decreased in CIS, and invasive tissue as compared to benign.
However, there was no significant difference of SOD3 protein expression between
patients with moderately and poorly differentiated tumors. Unexpectedly, patients
with poorly differentiated tumors had significantly higher levels of DCN protein in
benign tissue as compared to patients with moderately differentiated tumors
(p<0.05) (Figure 1-10). Poorly differentiated tumors had elevated total SOD3 in
benign tissue (p<0.05)(Figure 1-10). Nuclear PPARGC1A was significantly
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decreased in CIS tissue of patients with poorly differentiated tumors
(p<0.05)(Figure 1-10).
1.4.3.3 Alterations of SOD3 and PPARGC1A with tobacco usage
Tobacco usage is associated with increased risk of numerous cancers
including lung, and oral cancer (74,75). Lung and oral cancers have higher
incidence rates in Kentucky as compared to the national average (1,2). This
increased incidence of oral cancer is likely linked to Kentucky having higher
tobacco usage compared to the rest of the U.S. Therefore, we examined whether
tobacco use altered expression of our proteins of interest to identify how these
changes could contribute to cancer incidence. Out of the cohort of 77 patients,
58.4% were smokers (n= 45), and 13.0% were never users of tobacco (n= 10).
Individuals with unknown tobacco usage (n=21) or with mixed tobacco usage (n=1)
were excluded from analysis (Table 1-4). Total cellular SOD3 protein was
significantly higher in the benign tissues of never users as compared to smokers
(p<0.05) (Figure 1-11). However, upon tumorigenesis SOD3 protein decreased to
similar rates between smokers and never users. Never users may have increased
ability to combat oxidative stress in healthy tissues. Additionally, total and nuclear
PPARGC1A protein levels were significantly lower in CIS tissue of never users
(p<0.05) (Figure 1-11).
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Figure 1-10: Analysis of protein expression and tumor grade at diagnosis.
Nuclear and total cellular APE1, DCN, SOD3, NRF2, and PPARGC1A protein levels were in invasive HNSCC, as well as in
benign and CIS. Differences in protein markers were assessed between 29 samples with poorly differentiated tumors to 25
samples with moderately differentiated tumors. * Denotes statistical significance (p<0.05).
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Figure 1-11: Analysis of protein expression and tobacco usage.
Nuclear and total cellular APE1, DCN, SOD3, NRF2, and PPARGC1A protein levels were determined in benign, CIS, and
invasive HNSCC. These protein levels were compared for differences between 45 smokers and 10 never users. *Denotes
statistical significance (p<0.05).

1.4.3.4 Reduced SOD3 in p16 positive tumors
Strains of human papillomavirus (HPV) have been associated with the
development of oral cancer (6). As previously discussed in the introduction, p16
overexpression is an accurate surrogate marker for HPV infection (107). Because
HPV-induced p16 overexpression is linked to improved treatment response,
pathologists routinely determine the p16 status of oral cancers (107,168).
Therefore, we examined differences in APE1, DCN, NRF2, SOD3, and
PPARGC1A protein expression between p16 positive and p16 negative tumors.
Out of the cohort of 77 patients, 15.6% were p16 negative (n=12) and 39.0% were
p16 positive. Thirty-five patients were excluded from analysis due to unknown p16
status (Table 1-4). We observed no significant difference of APE1, DCN, NRF2,
and PPARGC1A between p16 negative and p16 positive tissues. In benign tissue,
there was significantly lower total cellular SOD3 protein in patients with positive
P16 status (p<0.05) (Figure 1-12). Patients with positive p16 status also had
reduced SOD3 protein in CIS, and invasive tissue as compared to patients with
negative p16 status (Figure 1-12). However, this difference was not statistically
significant. Although speculative, the increased oxidative stress that has been
attributed to HPV may lead to depletion of antioxidant SOD3 in benign tissues
(25,102,104).
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Figure 1-12: Analysis of protein expression and P16 status.
Nuclear and total cellular APE1, DCN, SOD3, NRF2, and PPARGC1A protein levels were determined in benign, CIS, and
invasive HNSCC. Differences in protein levels were compared between 12 patients with p16 negative tumors and 20
patients with p16 positive tumors. * Denotes statistical significance (p<0.05).

1.4.3.5 Delayed cancer onset in patients with higher SOD3
Cancer is largely a disease of age. Every year of life leads to accumulation
of genetic damage from oxidative stress that can lead to tumorigenesis. There has
been increased interest in whether antioxidant supplements can reduce age
related damage, and tumorigenesis (169). Therefore, we examined if patients who
developed cancer earlier in life had reduced levels of the antioxidant, SOD3.
Tissue samples were obtained from patients whose ages ranged from 41 to 77
(Table 1-4). Scatter plots were generated for total cellular or nuclear SOD3 levels
in benign, CIS, and invasive HNSCC, with age as a continuous variable (Figure 113). Individuals who developed cancer later in life were found to have significantly
higher levels of total and nuclear SOD3 protein in benign tissue (p<0.05) (Figure
1-13). It is unknown if these individuals maintained increased levels of SOD3
throughout their life or if other factors contributed to their delayed cancer onset.
Though speculative, the increased SOD3 levels in benign tissues may have
delayed tumorigenesis by reducing oxidative stress in tissues.
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Figure 1-13: Analysis of SOD3 Protein Expression and Age at Diagnosis.
Total cellular and nuclear SOD3 protein levels were determined in benign, CIS,
and invasive HNSCC. SOD3 protein levels were plotted against the patient’s age
at diagnosis. * Denotes statistical significance (p<0.05).
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1.5

Discussion

1.5.1 Potential biomarkers for identifying aggressive tumor phenotypes
One of the purposes of this study was to identify potential diagnostic and
prognostic biomarkers for use with HNSCC. We examined if altered expression of
APE1, DCN, NRF2, PPARGC1A, and SOD3 proteins correlated with reduced
survival, presence of lymph node invasion, and tumor grade. Identifying
biomarkers for these factors can alert physicians to individuals who are more likely
to have aggressive forms of cancer. This knowledge may alter treatment
strategies, and improve a patient survival.
Overexpression of APE1 in cancer tissues has been previously associated
with increased metastasis and reduced patient survival (20,109-112). In this study,
we identified that increased APE1 protein expression in CIS was associated with
decreased survival (Figure 1-7, Supplemental Figure C-2). Examining whether
APE1 protein in CIS correlates to poor survival is important, because improvement
of prognosis in the early stages of cancer may lead to improved treatment
strategies that could potentially prevent the formation of invasive cancer.
Additionally, this study identified that increased expression of total and nuclear
APE1 protein within CIS of the primary tumor was significantly associated with the
presence of lymph node invasion (Figure 1-9). Therefore, the reduced survival in
patients with increased APE1 protein in CIS is likely linked to the significantly
higher incidence of lymph node invasion in individuals with higher APE1 protein in
CIS (Figure 1-7). Due to the effect of field cancerization, there is substantial
overlap of mutations over a large tissue area. Because of this, early stage HNSCC
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may reflect genetic alterations that are present in proximal invasive cancers.
Therefore, identification of mutations associated with aggressive tumor
phenotypes in CIS may be useful in predicting lymph node invasion. Recently there
was a reported correlation between increased APE1 in the serum of individuals
with gastric cancer and the presence of lymph node invasion (170).
Analysis of gene expression in stage T4a HNSCC obtained from TCGA
demonstrated that increased APE1 was associated with reduced survival (Figure
1-8). This not only confirms that elevated APE1 is associated with significantly
reduced survival, but also indicates that this alteration occurs at the transcriptional
level. Further studies are needed to identify what increases APE1 transcription in
cancer tissues. Doing so could identify measures that prevent the APE1
overexpression that contributes to cancer progression and poor prognosis. This
study supports our observation that increased APE1 is associated with lymph node
invasion. Most importantly, these results support the potential of APE1 as a
biomarker for identifying patients at risk for increased metastatic potential.
Reduced DCN expression in tumors has been attributed to increased
mortality in cancer patients (126-132). Although there was a clear trend of
diminished survival in patients with low DCN protein expression in CIS, there were
not enough events to determine statistical significance (Supplemental Figure C3). An increased sample size will be needed to confirm whether reduced DCN
expression in cancer tissues is associated with significantly reduced survival.
Unexpectedly, increased DCN protein expression in benign tissue was associated
with reduced survival (Figure 1-7). The reduced survival in patients with increased
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DCN protein in benign tissue may be related to our observation that DCN protein
in benign tissue was significantly elevated in patients with poorly differentiated
tumor tissues (Figure 1-10). These results were unexpected, as many studies
have associated poor survival to decreased DCN expression. However, a
differential

proteomics

study

performed

using

breast

cancer

samples

demonstrated that increased DCN expression in the stroma and epithelium was
significantly associated with reduced overall survival (128). Thus, DCN protein
expression in benign tissue may still be a valuable biomarker in HNSCC.
Increased SOD3 expression in benign tissue proximal to the primary tumor
was associated with poorly differentiated tumors (Figure 1-10). Although SOD3
may be a valuable biomarker to identify patients who may be at risk for poorly
differentiated tumors, it is unclear as to how increased SOD3 protein in benign
tissue contributes to the development of poorly differentiated tumors. Although
SOD3 is recognized as a tumor suppressor, the SOD3 rs699473 single nucleotide
polymorphism has been associated with increased risk of high-grade or poorly
differentiated prostate cancer as well as an increased risk for adult brain cancer
(171-173). The exact role of how the SOD3 rs699473 polymorphism contributes to
the development of poorly differentiated cancers is unclear (173). The SOD3
rs699473 polymorphism is located within the SOD3 promoter region, but it is
unknown whether this polymorphism alters SOD3 protein expression (173). To the
best of our knowledge, there are no studies reporting this polymorphism within
HNSCC. Given that this SOD3 rs699473 has been implicated in poorly
differentiated tumors, future studies should examine whether this mutation is
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prevalent in HNSCC and if it is associated with increased SOD3 expression in
benign tissues.
1.5.2 SOD3 as a potential therapeutic target for patients at high-risk for
developing HNSCC
Tobacco usage is linked to increased oxidative stress in tissues (22,23,79).
Oxidative stress in lung tissues has been linked to depletion of the antioxidant,
SOD3 (64). Because chronic oxidative stress contributes to the development of
potentially oncogenic DNA mutations, we examined differences in SOD3 protein in
smokers versus never users. SOD3 was significantly elevated in the benign tissues
of individuals who never used tobacco as compared to smokers. Both groups of
individuals had HNSCC. However, the reduced levels of SOD3 in smokers may
further increase oxidative stress-induced cellular damage. As previously
mentioned in the introduction, chronic oxidative stress can lead to both inactivation
and depletion of SOD3 (29,64). In addition, we identified increased PPARGC1A
protein in the CIS of smokers as compared to never users (Figure 1-11). Although
the obvious step to prevent tobacco related lung and oral cancers is to avoid
tobacco usage, the highly addictive nature of tobacco limits successful cessation.
Therefore, understanding the changes that occur may allow for development of
other preventative measures to reduce the cancer burden in this state and globally.
Though speculative, supplementing the depleted SOD3 levels in smokers may
reduce oxidative stress and subsequent cellular damage.
HPV has been associated with increased oxidative stress within tissues
(25,104). As previously mentioned, oxidative stress can lead to the depletion of
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SOD3. We identified a significant decrease in SOD3 protein in the benign tissue
adjacent to p16 positive tumors (Figure 1-12). Identifying which antioxidants are
depleted in individuals at high-risk for HNSCC would support the development of
treatments to supplement antioxidant levels to minimize the development of
oncogenic mutations.
Cancer development can occur at any stage in life, but is typically related
to increased age. We identified that individuals who developed HNSCC later in life
had increased SOD3 protein in benign tissue, whereas individuals with decreased
SOD3 in benign tissue developed cancer at an earlier age. Though speculative,
individuals with increased SOD3 expression may have had better protection
against oxidative stress, which delayed cancer development. Supplementation of
SOD3 in individuals with depleted SOD3 may protect against early cancer
development.
1.5.3 Network of APE1 and associated factors
In this study, we examined how APE1 overexpression contributes to
HNSCC development and decreased patient survival. We hypothesized that
APE1’s role as redox dependent transcriptional regulator mediates suppression of
tumor suppressors and antioxidants. Previous research by our lab found that DCN
gene expression was suppressed by APE1 in mouse embryonic fibroblasts (122).
Loss of DCN has been associated with increased metastasis and mortality (126132). Therefore, we hypothesize that tumor development is supported by
decreased DCN expression in tissues overexpressing APE1.
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We identified elevated APE1 expression in tumor tissues, which is
consistent with previous observations (109,110). We also observed significantly
increased APE1 protein expression in CIS. To the best of our knowledge, APE1
overexpression has not been identified in the CIS of patients with HNSCC.
APE1 protein overexpression in cancer tissues appeared to downregulate
DCN. This was based on results demonstrating significant reduction of DCN
protein in cancer tissues alongside increased APE1 protein expression in cancer
tissues. There was also a significant negative correlation between APE1 and DCN
protein levels in CIS. However, analysis using transcriptome data obtained from
TCGA demonstrated no correlation between APEX1 and DCN gene expression in
either non-neoplastic or HNSCC (Table 1-2). This contradicts our IHC results and
previous results based on microarray analysis of mouse embryonic fibroblasts
(122). It is unclear as to why there was no significant correlation between APE1
and DCN gene expression in HNSCC tissues. However, it is possible these
differences are due to heterogeneity of tissues as compared to the immortalized,
monoculture cell lines.
We hypothesized that APE1 mediated downregulation of DCN and SOD3
through NRF2’s transcriptional regulatory activity. This hypothesis was based on
previous research supporting APE1 increases NRF2 activity, and research
demonstrated NRF2-mediated downregulation of DCN, SOD2, and SOD3(121).
We were able to observe a negative correlation of DCN and SOD3 protein levels
in relation to APE1 protein levels. In addition, we observed a positive correlation
between APE1 and NRF2 protein levels (Table 1-3). An inverse relationship of
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DCN, SOD2, and SOD3 gene expression relative to NRF2 was observed (Table
1-2). Upon searching for transcription factor binding sites within the DCN and
SOD3 promoter regions, we identified NRF2 binding sites in both DCN and SOD3
promoter regions (Table 1-1) (148-150). Therefore, APE1 and NRF2 may be
involved in reducing expression of DCN, SOD2, and SOD3.
1.5.4 Limitations of this study
1.5.4.1 Limitations in the efficiency of protein expression analysis
The protein expression analysis performed in this study is not yet optimal
for clinical usage. For this study, regions of benign, CIS, and invasive tumor had
to be first marked on each hematoxylin and eosin stained slide by a pathologist.
After immunohistochemistry staining, these regions had to be manually selected
for analysis using the Aperio ImageScope software. Analysis produced numerous
individual spreadsheets containing raw data, which needed to be carefully labeled
with the specimen and regions of analysis. These spreadsheets had to be merged
for each sample along with clinical data before any downstream analysis could be
performed. There is a long time delay between initial slide staining and final results.
Clinical testing must be rapid and accurate so as not to delay patient treatment,
which could result in increased mortality. In order to be practical for clinical
analysis, this process needs to be expedited without compromising data quality.
Currently, Aperio ImageScope software contains an algorithm to automatically
identify regions of tumor within a tissue sections. However, it is unknown whether
this can accurately determine regions of CIS. It is likely that a separate algorithm
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would need to be developed to automatically differentiate between benign, CIS,
and invasive tissue.
Samples were stained in large batches to minimize variance in staining that
otherwise would bring difficulty in assessing significant changes in protein levels.
This was important for preliminary identification of potential biomarkers. However,
these conditions would not be likely in a clinical setting. Collected specimens would
need to be assessed in a timely manner and would be stained individually or in
small batches. Specific protein expression cut off values are needed to group
patients as low or high risk.
1.5.4.2 Limitations in obtaining clinical data from patients across the state
Due to certain limitations of clinical data collection, we were unable to obtain
details of all clinical data. The University of Kentucky is the only NCI designated
cancer treatment center in the state of Kentucky and therefore has a substantial
catchment area. This leads to many patients being initially assessed and treated
at the university but with their follow-up care completed closer to home. Due to
this, it is not always possible to obtain a patient’s complete medical records. P16
status, tobacco usage, and lymph node assessment was not known for all patients
included in this study. Significant results were still found in these categories even
when excluding all unknowns. However, we may have obtained stronger statistical
power if expanded. In addition, there were no details on administered treatments
only as to whether a patient had chemotherapy, radiotherapy, and/or
immunotherapy. We were therefore unable to clearly determine if protein
expression correlated to a specific treatment resistance. To ensure access to
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complete treatment history, future studies can include individuals whose entire
treatment was performed at the University of Kentucky.
1.6

Conclusions
This study examined the role of APE1 in HNSCC development including

inhibition of tumor suppressors and antioxidants. APE1 is a key base excision
repair protein and is important in repairing oxidative DNA damage that may lead to
oncogenic mutations (20,38-40). Paradoxically APE1 overexpression has also
been reported to disrupt DNA repair coordination, and is associated with
tumorigenesis due to increased genomic instability (174). This genomic instability
has been attributed to accumulation of single strand breaks, which APE1 creates
as a normal part of base excision repair (174). We identified increased APE1
protein expression in early stage cancer, which supports that APE1 overexpression
occurs early in tumor development (Figure 1-6). Though speculative, APE1
overexpression in early stage cancer may increase genomic instability and
subsequent mutations leading to progression to invasive cancer. Risk factors for
head and neck cancer such as tobacco usage or HPV infection can increase
oxidative stress within tissues. We propose that this oxidative stress disrupts the
finely controlled balance of APE1 expression and contributes to tumorigenesis.
Though not certain from this study, APE1 overexpression may lead to increased
NRF2 activity. Increased NRF2 activity subsequently inhibits transcription of DCN,
SOD2, and SOD3. NRF2 transcriptional co-activator PPARGC1A may support
NRF2’s suppression of DCN, SOD2, and SOD3. The loss of antioxidants SOD2

75

and SOD3 leads to increased oxidative stress within the tumor microenvironment,
which further drives APE1 overexpression (Figure 1-14).
Although not all details of the ROS network were identified in this study, we
did identify several potential biomarkers for use in patients with HNSCC. In this
study, we identified biomarkers that were associated with aggressive tumor
phenotypes such as shortened survival time, poorly differentiated cancer, and
increased metastatic potential. Patient survival may be improved by the use of
biomarkers that identify patients with aggressive tumor phenotypes. Physicians
may more accurately tailor treatment, and increase surveillance of patients with
aggressive tumor phenotypes. In addition, biomarkers can identify potential novel
drug targets. APE1 inhibitors are currently being explored as to whether they can
effectively sensitize tumors to chemoradiotherapy (175). Improved treatment
strategy through characterization of tumor phenotypes, and identification of novel
drug targets may improve patient survival.
Digital image analysis of IHC slides allows the unique opportunity to
objectively measure altered protein expression in proximal benign, CIS, and
invasive tumors and often within the same slide. There are currently no clinically
validated algorithms for automatic detection of CIS, and the methods used in this
study are not timely enough to be used for clinical diagnostics. However, the
development of new algorithms may allow for more accurate and rapid
identification of biomarkers in the future.
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Figure 1-14: Summary model of the role of APE1 and NRF2 in suppression
of DCN, SOD2, and SOD3
We propose that oxidative stress promotes APE1 overexpression. APE1 binding
to NRF2 may increase NRF2’s transcriptional regulatory activities. NRF2
suppresses transcription of DCN, SOD2, and SOD3. PPARGC1A as a coactivator
potentially mediates NRF2’s inhibition of SOD2. Reduction of the superoxide
dismutases contributes to increased oxidative stress, which further drives APE1
overexpression.
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Synopsis
2.1.1 Background
The COP9 signalosome, composed of 8 subunits, is implicated in cancer
genetics with its deneddylase activity to modulate cellular concentration of
oncogenic proteins such as IkB and TGFβ. However, its function in the normal cell
physiology remains elusive. Primarily focusing on gene expression data of the
normal tissues of the head and neck, The Cancer Genome Atlas (TCGA) database
was used to identify groups of genes that were expressed synergistically with the
COP9 genes, particularly with the COPS5 (CSN5), which possesses the catalytic
activity of COP9.
2.1.2 Results
Expressions of seven of the COP9 genes (COPS2, COPS3, COPS4,
COPS5, COPS6, COPS7A, and COPS8) were found to be highly synergistic in the
normal tissues. In contrast, the tumor tissues decreased the coordinated
expression pattern of COP9 genes. Pathway analysis revealed a high coordination
of the expression of COPS5 and the other COP9 genes with mitochondria-related
functional pathways, including genes encoding the respiratory chain complex.
2.1.3 Conclusions
The results indicate that mRNA expression data for the matched normal
tissues available in TCGA are statistically reliable, and are highly useful to assess
novel associations of genes with functional pathways in normal physiology as well
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as in the cancer tissues. This study revealed the significant correlation between
the expressions of the COP9 genes and those related to the mitochondrial activity.
2.2

Introduction
The constitutive Photomorphogenesis (CSN) 9, or COP9 signalosome, is a

critical multi-functional structure in cells (176,177). COP9, originally discovered in
Arabidopsis thalania as a negative regulator of photomorphogenesis, was later
found to be highly conserved across many species (178,179). COP9 is a 450-550
kDA holocomplex composed of 8 subunits whose official gene symbols are listed
in Table 2-1 (176,180). COP9 has catalytic activity to remove Nedd8, a smallubiquitin like modifier, to regulate cullin-RING ubiquitin E3 ligases, and thus protein
degradation pathways mediated by cullin complexes (176). COP9 regulates
phosphorylation of proteins such as tumor suppressor p53, and neddylation
essential to ubiquitin-mediated proteolysis of key proteins including tumor
suppressor HIF-1α (181-185). Thus, COP9 has been an important focus in cancer
genetics (180,185-188).
Despite intense studies in the past, the exact essential role of COP9 still
remains unknown largely due to COP9's promiscuous property to interact with a
variety of cullin complexes and others, and to affect stabilities of a number of
cellular factors. Additionally, subforms of COP9 complexes were reported
(177,189,190). Dubiel et al. proposed that such flexible conformation enables the
broad range of substrates.
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Table 2-1: Nomenclature of mammalian COP9 genes

Table contains protein and gene names for COP9 subunits, their gene ID and
chromosomal location.
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Among the 8 subunits, COPS5 is the most extensively studied subunit
which has numerous critical functions including deneddylation reactions (176)
(185). It is commonly over-expressed in cancers leading to increased
deneddylation within cells (191). Other subunits have been shown to possess
unique functions. For example, CSN1/GPS1 is involved in stabilization of p53
(185,188). Over-expression of COPS2 is linked to chromosome instability
(188,192). Both COPS2 and COPS3 knockout are embryonic lethal at E3.5 and
E8.5 respectively (185,188). COPS6 is frequently over-expressed in cancer (185).
COPS8 knockout is also embryonic lethal (E7.5) with impaired growth and
differentiation (185). Although these reports convincingly indicate that all the
subunits have essential functions in mammalian cells, how these reported
functions contribute to COP9 activity remains largely unknown.
Identification of functional groups with which COP9 signalosome may
interact with in normal physiology may provide an important clue to understand
how dysregulation of COP9 may facilitate tumorigenesis.
Deficiency in even one subunit leads to COP9 destabilization. Downregulation of COPS5 in mouse embryonic fibroblasts drastically decreased the
stability of COPS1, COPS3, and COPS8 (193-195). Therefore, it is plausible that
coordinated expression of COP9 genes is needed to maintain necessary amounts
of COP9 and imbalance may be associated with disease (196). To elucidate this
possibility, a statistically adequate number of normal tissues must be analyzed with
precision for their gene expressions. Using cultured cell lines is not appropriate for
this investigation, because the cell lines established in vitro are all transformed and
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thus expressions of the COP9 genes are likely altered from cells in normal in vivo
conditions.
The Cancer Genome Atlas (TCGA) has procured specimens from more
than 500 human tumor tissues from various cancers for comprehensive analyses
of tumor tissues and advanced cancer genomics. Importantly, matched normal
tissues have been analyzed for about 10% of each cancer type. Using the TCGA
database, we elucidated the possibility that expression of the COP9 genes are
synchronized in the normal cells, and such coordinated gene expression is
impaired in tumors. We found that the quality of the data from normal tissues was
sufficiently high to test this possibility. Indeed the COP9 gene expressions were in
synergy in the normal tissues, but this fine coordination was lost in the tumor
tissues. Furthermore, the analysis led to the unexpected observation that the
expressions of the COP9 genes were highly synchronized with those involved in
mitochondrial biogenesis, particularly those of respiratory chain complex.
2.3

Methods

2.3.1 Nomenclature of COP9 Genes
Although the gene names from CSN1 to CSN8 are intuitive and have been
accepted as the names for the COP9 subunits (197), the TCGA uses the official
gene symbols (Table 2-1). For the simplicity, this study used the official gene
symbols as the subunit names.
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2.3.2 Data Obtained From TCGA
The mRNA expression data of normal and tumor tissues were obtained
through TCGA's online data portal site (http://cancergenome.nih.gov). The cancer
tissues chosen for this study are 44 normal and 522 cases of head and neck
squamous cell carcinoma, lung adenocarcinoma (50 normal and 502 tumor).
Normalized gene expression results (mRNASeq2 level3) were collected. Each set
of mRNA expression data contained 20,531 gene entries, which were linked to
annotations through DAVID functional gene annotation database (Database for
Annotation, Visualization and Integrated Discovery; https://david.ncifcrf.gov),
yielding 20,154 analyzable gene lists. The information linked to the mRNA data is
chromosome

cytoband

and

gene

ontology

(GOTERM_BP_FAT,

GOTERM_CC_FAT, GOTERM_MF_FAT, and KEGG_PATHWAY).
Similarly, the de-identified clinical information including anatomical sites and
smoking history were retrieved from TCGA. Data processing and analysis were
carried out using R (ver 3.1.2) and series of command line programs developed
with the Swift language using Xcode ver. 6.
2.3.3 Generation of Correlation Coefficient Table Specific for Individual
Genes
Gene expression data of normal and tumor tissues from donors were
assembled into a single table file consisting of columns of tissues and rows of
genes. Genes that show zero mRNA values in more than 5% of the tissues
analyzed were excluded. Pearson correlation coefficient (r) values between
expressions of a target gene (example COPS5) and each of all the other genes
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were determined, and the genes were then sorted based on r-values. Significance
of r-values were assessed with p values calculated with cor.test function in R, i.e.,
cor.test (A, B, method = "Pearson", alternative = "two.sided") where A and B are
two mRNA expression vectors with an equal dimension (= number of samples).
Pair and boxplots were drawn for particular gene sets using R.
2.3.4 Cytoband Plot and Generic Graphical Presentations
Genes ranked within 500 highest |r| values were pooled, and the cytoband
information was processed into float values by the simple formula as following. For
a gene with cytoband of ApB.N or AqB.N, a float value was generated by A (B.N)/100 or A + (B.N)/100, respectively. For example, 8p11.2 was converted to 8
- 11.2/100 = 7.888, and 8q11.2 was to 8.112. Values of (x, y) = (cytoband, r) was
plotted using R. X and Y chromosomes were shown in one column as all analyzed
genes mapped in X chromosome were also found in Y chromosome.
2.3.5 Interpretation of Functional Gene Annotation
Top 1000 genes with the highest |r| values were pooled with each gene
accompanying gene ontology (GO) and KEGG pathway information. Overrepresented pathways are sorted by the p values based on binomial distribution: 1
- pbinom (n, 1000, µ) (in R), where n is the actual count occurring in the 1000
genes, and µ is the average of finding the particular pathways, and calculated with
the whole gene set of 20,154.
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2.3.6 Derivation of Enrichment Score (ES)
The ES scores were calculated by the method described previously (198).
For example, for ES of oxidative phosphorylation (KEGG pathway hsa00190), the
COPS5 correlation coefficient table with gene annotations was scanned based on
association with "hsa00190" to generate Phit - Pmiss. ES was provided as the
maximum value of Phit - Pmiss as described (198). A histogram of ES values was
calculated with randomly chosen Nh genes for iteration of 1000, and the distribution
was used to assess the statistical significance. Enrichment scores and
corresponding p values were calculated for all genes and then false discovery
rates were determined as described above.
2.4

Results

2.4.1 A single gene expression analysis
COPS5 (official gene symbol of CSN5) is responsible for the
deneddylation activity of the COP9 signalosome, and also known as Jab1 to
activate c-Jun (Jun-activating/binding protein). Thus, most COP9 studies have
focused on the activity of COPS5 (199) and its influence on biological activities
including tumorigenesis. Because of the pivotal role of COPS5 for the COP9
signalosome in mammalian cells, this study primarily focused on COPS5 to
investigate the possibility of coordinated expression of the COP9 subunits in the
normal and tumor tissues. Our primary interest was the head and neck squamous
cell carcinoma (HNSCC), where effects of smoking and influences of major genetic
factors, including p53, p16, AKT1 and K-Ras could be addressed due to its
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established cancer etiology involving these genes. In addition, HNSCC data in
TCGA included a few distinct anatomical sites including oral cavity, tongue and
larynx, and thus effects of tissue sites for the gene expression could be elucidated
with the clarified clinical record. Therefore, this study mainly focused on the
HNSCC. For the simplicity, the official gene symbols will be used in this study
instead of more commonly used protein names (Table 2-1).
Expression of the COPS5 gene was examined using the data of 44 normal
head and neck tissues available in TCGA. COPS5 expression in normal tissues
showed mean value of 1261.0 with standard deviation (sd) 328.83 and coefficient
of variation (sd/mean) 0.26. As a comparison, mean coefficient of variation of the
15,660 gene set was calculated, and found to be 0.693 (± 0.575). Therefore, the
COPS5 gene expression appeared to be relatively stable among normal oral
tissues.
2.4.2 Coordinated expressions of the COP9 genes in normal tissues
Expression patterns of COPS5 and other COP9 genes were elucidated by
comparing correlation coefficients (expressed as r thereafter), using the RNA
expression data (RNAseqV2 level 3). High positive correlations were found among
the COP9 gene expressions. Specifically, relative to COPS5, all the other COP9
genes except COPS7B showed statistically significant positive r-values (Table 22 and Figure 2-1). GPS1/CSN1 showed a smaller r-value than the others, namely
COPS2, COPS3, COPS4, COPS6, COPS7A, and COPS8. The lower correlation
of gene expression of GPS1 vs. COPS5 was found to be a
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Table 2-2: Correlation of expression of COP9 genes in normal oral tissues

Pearson correlation coefficients were calculated using RNA expression data
collected from TCGA. Data from 44 patient specimens were analyzed. P values
were calculated as described in methods.
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Figure 2-1: Pair-wise plot of expressions of COP9 genes
The RNA expression results from normal 44 oral tissues are plotted. 1: GPS1, 2:
COPS2, 3: COPS3, 4: COPS4, 5: COPS5, 6: COPS6, 7A: COPS7A, 7B: COPS7B,
8: COPS8.
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Figure 2-2: Expressions of COP9 genes in normal oral tissues

The RNA expression levels (y-axis) of COP9 genes from 44 normal oral tissues
are shown. Horizontal lines in the boxes: median values. Top and bottom whiskers
denote the first and the third quartile (Q1 and Q3). Outliers (> Q3 + 1.5 * (Q3 - Q1)
and < Q1 - 1.5 * (Q3 - Q1)) are shown as individual dots.
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general characteristic through our analyses in this study. However, the positive
correlation between GPS1 and COPS5 was still statistically significant (p = 0.011).
In addition to the low r-value relative to the other COP9 genes, the level of
COPS7B expression was significantly lower compared to COPS7A (Figure 2-2).
These results indicated that the expressions of COP9 genes were
synchronized in human normal oral tissues. Leppert et al. recently observed that
mRNA levels of COP9 genes were regulated by an miRNA let-7 for synchronization
(196). To probe the importance of the regulatory mechanism by miRNA, the TCGA
miRNA dataset was used to determine the gene expression correlation of COP9
genes and the let-7 miRNA species (Table 2-3). There were statistically significant
negative correlations between let-7 isoforms (7a, 7b, 7c, 7e, 7f-2, 7g) and COP9
genes (GPS1, COPS5, COPS6, and COPS8), which was consistent with previous
work.
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Table 2-3: Correlation of let-7 miRNA and COP9 genes

The let-7 expression profile was obtained from TCGA for the matched normal and
tumor tissues of head and neck. Correlation coefficients for individual let-7
isoforms relative to COP9 genes are shown. (*) Asterisks indicate statistical
significance (p < 0.05).
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2.4.3 Loss of synergistic expressions of the COP9 genes in cancer tissues
To determine whether the synergistic expressions of the COP9 genes are
maintained in the cancer tissues, 42 tumor tissues matched to the normal cases
were pooled (2 normal cases could not be matched based on the id tag), and
determined their correlation coefficients (Table 2-4). High positive r-values were
observed among COP9 genes in normal tissues as expected. In contrast, the
correlations of expressions among COP9 genes diminished in the matched tumor
tissues (Table 2-4 and Table 2-5). Moreover, the negative effect of let-7 miRNA
observed in the normal tissue dataset was diminished in the matched tumor tissues
(Table 2-3). These results demonstrated that the coordinated expression of COP9
genes was lost in these tumor tissues.
2.4.4 Validation of the results with subgroups (age, anatomical sites, and
smoking history)
HNSCC is an age-related disease. The majority of specimens in TCGA are
from elderly patients (median = 61; the first quartile = 53, the third quartile = 69),
and less than 4% of the patients are younger than 40 years old. Thus, the loss of
the coordination of the COP9 gene expressions may be due to the age-related
degeneration of the coordination. However, we analyzed the COP9 expression in
the 31 tumor tissues that were 42 years old or younger to the 30 tumor tissues that
were 80 years old or older (Table 2-6 A and B). With this analysis, we found similar
loss of the coordinated expressions in specimens from both the young and elderly
patients. In addition, there were no significant differences of the expression levels
of each COP9 gene between the young and RNA-Seq data
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Table 2-4: Loss of coordinated COP9 gene expression in HNSCC

Normal and matched HNSCC tissues (sample number = 42) were compared for
their correlation coefficient values among the COP9 genes.
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Table 2-5: Loss of synchronized expression between COPS5 and the other
COP9 genes in tumor tissues.

To support the result of Table 2-4, which included 42 cases of matched head and
neck tumor tissues, 2 additional normal head and neck tissues were included to
calculate correlation of expressions among the COP9 genes. To compare the
results with the tumor specimens, correlation coefficients of COP9 genes versus
COPS5 (rCOPS5) were determined from randomly selected 44 tumor specimens
from the entire pool of 511. The calculations were repeated for 10,000 times to
obtain their averages and standard deviations. The distributions followed normal
distribution pattern, which were used to compare the difference from rCOPS5 of
normal tissues.
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from young (30 specimens) and elder patients (31 specimens) were used to
calculate the correlation coefficients among the COP9 genes in aged populations
(Table 2-6 C). Therefore, we conclude that the age is not a factor that affected the
low coordination of the COP9 genes in the tumor specimens.
The oral tissues in TCGA were taken from different anatomical sites (oral
cavity, tongue, etc.). The synergistic expression of COP9 subunit genes may vary
depending on the exact site of oral tissues. To assess this possibility, the data set
was arranged into subgroups based on the sites. The major groups were the oral
cavity (14 specimens) and the oral tongue (13 specimens). The data sets of the
two subgroups were used to determine correlation coefficients of the COP9 genes.
These values were similar to those of the entire dataset (Supplemental Table 27 and Table 2-8), indicating that the synergistic expressions of the COP9 genes
are maintained regardless of the sites of the oral tissues. Similarly, there appeared
to be no clear effects of smoking, because analyzing the normal tissues from
eleven current smokers identified highly similar synergistic RNA expressions of
COP9 genes (Table 2-9).
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Table 2-6: Loss of COP9 expression coordination in tumor tissues
independent of age.

RNAseq data from young (30 specimens) and elderly patients (31 specimens)
were used to calculate the correlation coefficients among the COP9 genes.
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Table 2-7: Synchronized COP9 expression in normal oral cavity tissues

14 normal tissues from the oral cavity were pooled based on the clinical data in
TCGA, and correlation coefficients as well as p values for COPS5 were calculated
as described in the main article.

Table 2-8: Synchronized COP9 expression in normal tongue tissues

Data based on the 13 normal tongue tissues were pooled based on the clinical
data in TCGA, and correlation coefficients as well as p values for COPS5 were
calculated as described in the main article.

98

Table 2-9: Synchronized COP9 expression in normal oral tissues of smokers

11 normal tissues from smokers were pooled based on the clinical data in TCGA,
and correlation coefficients as well as p values for COPS5 were calculated as
described in the main article.
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2.4.5 Chromosome mapping of genes with expressions highly correlated
with COPS5
To elucidate the tumor-associated disintegration of the COP9 gene
expression in detail, we focused on the COPS5 gene. We generated a "correlation
table" of the COPS5, in which expressional correlation coefficients relative to the
COPS5 gene (rCOPS5) were calculated for all the analyzable genes (about 14,000
genes). By cross-referring the results to gene ontology provided with DAVID, we
noticed that genes with high rCOPS5 of the tumor tissues were mapped in the same
chromosomal location as the COPS5 gene (8q13.2, Table 2-1). We thus
speculated that the loss of the coordination of the COP9 expressions in the tumor
tissues was not due to unpredictably disorganized expressions of the COP9
subunit genes, but rather there was a dominant effect of the physical locations of
the genes on their expressions. To illustrate this possibility, chromosomal locations
of 500 genes with top |rCOPS5| values were plotted based on the chromosome 8
based on the cytoband (Figure 2-3, top). The genes with high |rCOPS5| in the normal
tissues were distributed through all the chromosomes; among the top 100 genes,
only 7 genes were mapped at 8q, near the COPS5 chromosomal location (8q13.2).
In contrast, genes with high |rCOPS5| in the tumor tissues were concentrated near
COPS5's chromosomal region (Figure 2-3, bottom); 56 genes out of the top 100
genes were bound to 8q.
We sought to assess the chromosomal cis-effect on the COPS5 gene
expression more objectively. To this end, we determined the enrichment score (ES)
(198) based on the |rcops5| for the genes located within 1 mega base pairs
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Figure 2-3: Chromosomal mapping of genes with highly synchronized
expression with the COPS5 gene.

The 500 highest ranked genes based on |rCOPS5| were pooled, and mapped on to
chromosomal locations based on their cytoband information. In the top panel, a
cartoon denotes the chromosome 8 (at 8 in x-axis) where the COPS5 gene is
located (8q13). The major grid marks on the x-axis (1 - 22 and X/Y) depict location
of centromeres dividing p and q arms at the left and the right sides, respectively.
X and Y chromosomes are combined, because all genes analyzed in the figure are
mapped in both X and Y.
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(Mbp) from the COPS5, and obtained a p-value based on the null hypothesis that
these ES values were not different from that calculated for genes outside 1 Mbs
from the COPS5. We have also determined such ES values for all the genes in the
chromosome 8 to determine false discovery rate (FDR, q). The ES value for the
COPS5 with the tumor tissues (ES = 0.65, p = 0.02, q = 0.043) was significantly
higher than that with the normal tissues (ES = 0.39, p = 0.27, q = 0.49). The
procedure was applied for the other COP9 genes, and revealed significant links to
the chromosomal cis-effect in case of the tumor tissues (Table 2-10). Therefore,
we conclude that the COP9 expression in the tumors is disintegrated because the
chromosomal cis-effect becomes a dominant force to express each subunit gene.
Furthermore, these results indicated that analysis of the COP9 expressions in the
normal tissues rather than tumor tissues is pivotal for understanding the COP9's
role in vivo, and such an analysis is possible using the RNA-Seq data in the normal
tissues available from TCGA.
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Table 2-10: Effect of relative distance in chromosomes on the gene
expression correlation

Nh: number of genes found within 1 Mbp of each COP9 gene; mean, sd, p and q
values were determined as described in materials and methods. Overall, highly
significant ties of the gene expression correlation with the chromosomal locations
were found in tumor tissues, while in normal tissues there were no such effects of
the chromosomal locations on the gene expression co-expression (except for
GPS1 and COPS6).
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2.4.6 Pathway analysis based on KEGG and GO revealed association of
COPS5 expression with mitochondrial pathways
Genes that belong to particular cell pathways may be over-represented in
the COPS5 correlation coefficient table. Identifying such pathways should provide
important clues as to COP9's roles under the normal physiology. Based on the
results above, such functional association should be elucidated with the data
derived from normal tissues, and the large pool of high-quality gene expression
data in the TCGA database prompted us to investigate this possibility. Genes with
the top 1,000 |rCOPS5| values in the normal tissues were pooled, and functional
pathways available through GO and KEGG database were associated to each
gene (Supplemental Table D-1). The GO and KEGG pathways were then ranked
based on the over-representation, and the 20 most over-represented pathways are
shown in Table 2-11 (the expanded list is shown in Supplemental Table D-2).
Unexpectedly, the pathways belonged to those related to mitochondrial functions
and components. For example, 61 genes belonging to the oxidative
phosphorylation KEGG pathway (hsa00190) were among the genes with high
expression correlation with COPS5 out of 106 total genes (p < 1.1e-16). A number
of GO pathways involving mitochondrial functions were also found among the overrepresented pathways. These included respiratory chain (GO:0070469),
mitochondrial electron transport (GO:0006120), NADH dehydrogenase activity
(GO:0003954), mitochondrial respiratory chain complex I (GO:0005747). In fact,
all of the 20 most over-represented pathways are directly related to major
mitochondrial and energy derivation functions.
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Table 2-11: Association of COPS5 with mitochondrial pathways in normal
oral tissues
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Dataset includes the top 1000 functional pathways found in high correlation with
Found: number of genes in a particular GO or KEGG pathway found in the top
1000 rCOPS5 list; Expected: number of expected genes to yield p < 0.05 appearing
in 1000 genes based on the average appearance per gene (µ); µ values were
calculated by the total appearance of individual pathways in the entire gene list of
20,154. P values were calculated using binomial distribution in R. Expected
occurrences in a list of 1000 genes to provide p < 0.05 are listed.
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At the time this study was carried out, gene ontology database had not yet linked
COPS5 to any of mitochondrial-related pathways. Expression values were
examined in pair-plots for COPS5 and mitochondrial genes of the five highest
rCOPS5, NDUFB6, MRPS36, ATP5F1, TMEM126A, NDUFB3 (Figure 2-4). The
results illustrate high integrity of the data and the coordination of the expression of
the COPS5 with the mitochondria related genes.
Dependency on the anatomical sites and smoking history were tested with
the same subgroups as described above (Supplemental Table D-3). The mRNA
expression data from the two major anatomical sites, oral cavity and oral tongue,
resulted in almost identical over-representation of the mitochondrial pathways with
COPS5. The same conclusion was made with the subgroup containing only the
current smokers.
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Figure 2-4: Pair-wise plot for RNA expression 5 mitochondrial genes
The five genes with the highest rCOPS5 in the normal oral tissues are plotted. 1:
COPS5, 2: NDUFB6, 3: MRPS36, 4: ATP5F1, 5: TMEM126A, 6: NDUFB3.
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2.4.7 Alteration of COPS5 expression coordination in cancer tissues
The gene expression coordination between the COPS5 gene and the
mitochondrial pathways was elucidated with tumor tissues (Table 2-13 and
Supplemental Table D-4). Although a few GO pathways related to mitochondrial
functions were over-represented, major pathways associated with the COPS5
expression were those involved in ribosome processing and RNA binding as well
as membrane lumen pathways.
The possibility that tissues from a particular anatomical site with high
dysregulation caused the bias was addressed. Oral cavity, tongue, and larynx are
the major 3 sites that together contribute to about 80% of the donated head and
neck cancer tissues. COPS5-associated GO and KEGG pathways were
determined for the tissues from the particular sites, and confirmed that correlation
of COPS5 expression with mitochondria associated genes were not as
predominant as in the normal tissues.
To further support the finding, enrichment score (ES) was calculated for
the genes in the oxidative phosphorylation KEGG pathway (hsa00190) using RNASeq data of 44 normal head and neck tissues deposited in TCGA (198) (Figure 25 A). The obtained ES value, 0.797, was much higher than the average ES value
based on randomly assigned gene pools (Figure 2-5 B).
In addition, ES values corresponding to all the other KEGG pathways were
calculated for the 42 matched normal and tumor tissues (Table 2-14). The ES
values of the oxidative phosphorylation pathway (hsa00190) were found to be
among the highest. The ubiquinone biosynthesis pathway generated the highest
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Table 2-12: Loss of coordinated expression of COPS5 with mitochondria
related genes in the tumor tissues

The analysis was carried out in the same way as for Table 2-11
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Figure 2-5: Enrichment score for KEGG oxidative phosphorylation pathway
(A) The enrichment score was calculated for the oxidative phosphorylation KEGG
pathway (hsa00190). Genes are aligned on x-axis based on their correlation
coefficients to the COPS5 expression. The hsa00190 pathway contained 106
genes in the entire list. (B) 106 randomly selected genes were used to calculate
ES using the rCOPS5 gene list as in A. The histogram was generated by iteration of
1000 times. The arrow indicates the ES for hsa00190.
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Table 2-13: Enrichment scores for the COPS5 gene on KEGG pathways

All KEGG pathways found in the entire gene list of TCGA RNA expression
database (199) were individually scanned through the rCOPS5 alignment, and the
maximum (ES) as well as minimum (Phit - Pmiss) were calculated as previously
described (198). The KEGG pathways that generated the 10 highest ES values
are shown. Nh: number of genes belonging to a KEGG pathway in the entire list. A
p value for a particular KEGG pathway with an Nh (= No) was determined using
mean and standard deviation obtained by the following method. No genes were
randomly selected from the rCOPS5 list and calculated an ES value, which was
reiterated for 1,000 times to generate the mean and standard deviation of ES.
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ES value, which is an essential factor in the respiratory chain and requires
phenylalanine (generating the second highest ES) for its synthesis. Thus, the
enrichment of genes involved in mitochondria-related pathway based on the
COPS5 correlation was exceptionally high.
To elucidate the significance of the COP9 coordination with oxidative
phosphorylation compared to other genes, we calculated ES values relative to the
hsa00190 KEGG pathway for the entire gene list in the RNA-Seq data of the
matched normal and tumor tissues to obtain FDR (Table 2-15, 2-16). Except for
the COPS7B gene, all the COP9 subunit genes showed highly significant
correlations with the genes in the oxidative phosphorylation pathway. Remarkably,
while most of the genes belonging to the oxidative phosphorylation pathway
resulted in the high ES/low FDR values, the COP9 genes (except for COPS7B)
were ranked comparably with these genes. Again, the p as well as FDR values
were increased for all the COP9 genes with the tumor specimen set, indicating that
tumor tissues have lost the link of COP9 expression to the oxidative
phosphorylation related genes. Taken all together, there results imply that the
normal physiological function of the COP9 may be inseparable from the
mitochondrial activity
2.4.8 Analysis of gene expression of other cancers in TCGA
Finally, the question was addressed whether the association of the
expressions of COP9 genes with those of mitochondrial genes was unique in head
and neck tissues. To probe this, the RNA expression data of TCGA for the lung
squamous cell carcinoma tissues were analyzed. Tumors originating from
113

Table 2-14: ES for COP9 genes for all KEGG pathways

For each COP9 gene correlation coefficient table, ES values were calculated for
all KEGG pathways. Mean, standard deviation (sd), p and q values were calculated
as described in the method section. Extremely high correlations of the COP9
genes (except for GPS1 and COPS7B) found in normal tissues were decreased
significantly in tumor tissues (especially for COPS2 and COPS5).
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Table 2-15: ES for COP9 genes for the oxidative phosphorylation pathway

ES values for all genes in RNAseq data were calculated for the oxidative
phosphorylation KEGG pathway (hsa00190). Mean, standard deviation (sd), p and
q values were calculated as described in the method section.
The extremely high correlations of the COP9 genes with hsa00190 were found
among normal tissues, whereas such correlations were decreased significantly
among tumor tissues, especially for the COPS4, COPS5, and COPS7A genes.
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the lung upper airway epithelia share similarity with HNSCC in its etiology and its
involvement of smoking as an important risk factor. First, the synergistic
expression pattern of COP9 genes in the normal tissues (n = 50) was examined,
and found to be highly synergistic with one another (Table 2-16 and Figure 2-2).
Exceptions were GPS1 and COPS7B, which showed lower correlation coefficients
to other COP9 factors. The high positive correlations were again lost in the tumor
tissues. These results showed a remarkable coincidence with those of head and
neck normal and tumor tissues.
The functional pathway analysis with the entire gene list resulted in the
high correlation of the COPS5 expression with the mitochondrial genes
(Supplemental Table D-4). Unlike the case of head and neck squamous cell
carcinoma, however, the coordinated expression of COP9 and the mitochondrial
genes was maintained well in the lung squamous cell carcinoma tissues
(Supplemental Table D-4).
2.5

Discussion
Cancer genetics and analyses of the TCGA database mainly focus on

the loss of genomic integrity. Mutations and single nucleotide polymorphism in
DNA show the high rate of permanent alteration of the genome, epigenetic
modification of the genome, RNA and miRNA expression alterations. TCGA data
sets are available publicly for these types of analyses. The database is highly
reliable and allowed us to examine cancer genomics with more than 500 tumor
specimens (200).
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Table 2-16: Synchronized expression of the COP9 genes in the matched
tissues of normal and lung squamous cell carcinoma

The analysis was carried out in the same way as for Table 2-3.
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In addition to the tumor specimens, data from about 40 to 50 normal tissues
are made available for most types of cancers with a notable exception for
glioblastoma. Although the data sizes are smaller than those for the cancer tissues,
they are arguably one of the most comprehensive data for genomics of human
specimens of non-disease status with pathological scrutiny, which should provide
valuable information for elucidating functions of a gene under the normal
physiology. We hypothesized that a synergistic expression of genes may be
observed in the normal tissues, when expressions of a group of genes need to be
coordinated for their proper cellular activities. COP9 signalosome is an ideal
subject to test this possibility, because all 8 subunits are essential for the proper
COP9 function; deficiency in one of the COP9 genes decreased stability of the
other subunits and caused lethality (199,201). In this study the COP9 signalosome
genes showed highly synergistic expressions in the normal head and neck tissues,
except for GPS1 and COPS7B. Remarkably, these characteristics, including the
lower r-values for GPS1 and COPS7b, were maintained well even in the lung and
breast (data not shown) normal tissues. The coordinated expression of the COP9
genes decreased in the tumor tissues. Therefore, this coordination could not have
been detected by analyzing tumor tissues. Likewise, because all cells cultured in
vitro are under non-physiological conditions and thus transformed at some extent,
it would have been difficult to obtain convincing evidence for the expression
correlation of the COP9 subunit genes based on in vitro cell biological studies
alone.
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It is interesting to observe the lowest coordination of GPS1 expression
compared to the other COP9 components (excluding COPS7B). Besides being a
subunit of COP9, GPS1 is known for its function in suppression of G-protein and
mitogen-activated signal transduction in mammalian cells (202). This COP9independent function quite likely requires a regulation of the GPS1 gene separate
from the other COP9 genes.
COPS7B not only had the lowest r-value, but also significantly lower
expression compared to COPS7A (Figure 2-2). While COPS7A and COPS7B
genes are encoded in different human chromosomes, chromosome 12 and 2
respectively, there is a high homology between COPS7A and COPS7B in the
amino acid sequence (78% identical). Thus, COPS7B may have only a minor
functional role for COP9, which may be compensated by COPS7A.
To our knowledge, one of the approaches in this study, using the exact
physical map of the transcription start sites available from the Ensemble genome
database, has not been applied previously to elucidate effects of the relative
locations of genes on the gene expression correlations. In this study, we used this
approach to find the chromosomal locations of the genes as a dominant factor
causing the loss of the coordinated expressions of the COP9 genes. This cis-effect
was not found in the normal tissues in most genes, an indication that expression
of most genes in normal tissues are regulated based on their functions and
independently from their chromosomal locations. Therefore, important implications
derived from this analysis are that 1) analyzing tumor tissue data may not identify
a function of a protein family such as COP9, and 2) the qualities of the normal
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tissue data available in TCGA are high enough to help identifying unknown
expressional linkages with functional pathways. Although the primary focus of this
study was COP9 expression profiling, we expanded the analysis of the influence
of the chromosomal location for all the genes that were analyzable in the RNA-Seq
data, and the data for cancer genes (hsa05200) are shown in Supplemental Table
D-5. It may be interesting to elucidate whether these proto-oncogenes show tight
association with the chromosomal locations in other types of tumor tissues
available in TCGA.
The observation that the expression of the COPS5 gene (and therefore the
other COP9 genes) was synchronized with those involved in mitochondrial function
was unexpected. The correlation coefficients of the COPS5 and top ranked genes
such as NDUFB6 and MRPS36 (Figure 2-4) were remarkably high with statistical
significance. Moreover, not only a handful of genes involved in mitochondria but
also the total pathway analysis revealed that mitochondria-related cellular
functions and pathways were predominantly over-represented in the COPS5
correlation coefficient table. Although there have not been reports that show direct
function of COP9 for mitochondria, correlation analyses with the genes of which
functions have been extensively studied (i.e. TP53 and CDKN2A) linked these
genes with predicted cellular functions. These results validate the approach in this
study and support the prediction that the COP9 signalosome has a novel functional
link to mitochondrial activities (Supplemental Table D-6).
Few studies have linked COP9 to mitochondria-related cellular activities.
Jab1/COPS5 was previously identified as an apoptosis inducing factor through

120

modulation of mitochondrial BH3-domain containing protein BclGs (203). A study
found that in Neurospora crassa, 3 subunits of the COP9 were required to recover
from deficiency of alternative oxidase function, which is important for mitochondrial
function (204). However, no follow-up studies have been carried out for
mammalian cells. On the other hand, pathways involved in ribosomal functions
were associated with the COPS5 expression in the tumor tissues. The significance
of this link is currently unclear. However, the COP9 structure is homologous to
translation initiation factor 3 (eIF3), another high-ordered complex in the cells
(205), and our speculation is that COPS5 may have an overlapping function in the
protein synthesis in transformed cells.
The quantity and quality of the genomics database will only be improved.
The present study underscores the importance and usefulness of examining the
genomics of normal tissues. The results would provide novel functional links of a
gene, which was not possible by analyzing the data set of pathophysiological
specimens. This approach can reasonably be applied to other genes to identify
pathways that have not been known due to scarce information for genomics
information of normal tissues.
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2.6

Conclusions
The present study investigated COPS5 gene expression using the TCGA

database. The analysis revealed the highly synergistic mRNA expression pattern
among COP9 genes in normal oral tissues. The coordination was abrogated in the
tumor tissues, and the regulatory mechanism was taken over by a cis-acting gene
regulation. Further analysis revealed an unexpected expression correlation
between the COPS5 gene and a number of mitochondria-related genes,
postulating the possible functional role of the COP9 signalosome for mitochondrial
activities. The quality of the RNA expression data available in TCGA is high enough
to allow us gene expression analysis in normal tissues to identify gene functions
under normal physiology, which may not be recognized by the data obtained from
tumor tissues.
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3.1

Synopsis
Apurinic/apyrimidinic endonuclease 1 (APE1) is an essential protein crucial

for repair of oxidized DNA damage not only in genomic DNA but also in
mitochondrial DNA. Parkin, a tumor suppressor and Parkinson's disease (PD)
associated gene, is an E3 ubiquitin ligase crucial for mitophagy. While DNA
damage is known to induce mitochondrial stress, Parkin's role in regulating DNA
repair proteins has not been elucidated. In this study, we examined the possibility
of Parkin-dependent ubiquitination of APE1.
Ectopically expressed APE1 was degraded by Parkin and PINK1 via
polyubiquitination in mouse embryonic fibroblast cells. PD-causing mutations in
Parkin and PINK1 abrogated APE1 ubiquitination. Interaction of APE1 with Parkin
was observed by co-immunoprecipitation, proximity ligation assay, and colocalization in the cytoplasm. N-terminal deletion of 41 amino acid residues in
APE1 abrogated the Parkin-dependent APE1 degradation. These results
suggested that Parkin directly ubiquitinated N-terminal Lys residues in APE1 in the
cytoplasm. Modulation of Parkin and PINK1 activities under mitochondrial or
oxidative stress caused moderate but statistically significant decrease of
endogenous APE1 in human cell lines including SH-SY5Y, HEK293, and A549
cells. Analyses of glioblastoma tissues showed an inverse relation between the
expression levels of APE1 and Parkin. These results suggest that degradation of
endogenous APE1 by Parkin occur when cells are stressed to activate Parkin, and
imply a role of Parkin in maintaining the quality of APE1, and loss of Parkin may
contribute to elevated APE1 levels in glioblastoma.
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3.2

Introduction
Oxidatively damaged DNA is primarily repaired by DNA base excision

repair. In the mammalian DNA base excision repair pathway, apurinic/apyrimidinic
(AP) endonuclease (APE1) incises DNA upstream of AP sites to generate singlestrand breaks (SSBs) with 3’-OH termini for subsequent DNA repair synthesis
reactions (206).

APE1 is shown to be essential during mouse embryonic

development and is the only active AP-endonuclease in mammals. Studies also
demonstrated that APE1 was indispensable for cultured cells (123,207), although
recent studies demonstrated that cells derived from a B lymphocyte line could
survive without APE1 (208,209). APE1 also functions as a gene expression
regulator by redoxically activating oncogenic and pro-survival transcription factors
such as AP-1 and NF-κB, and is also involved in gene regulation necessary for
calcium homeostasis (39,117). Therefore, APE1 is a pro-survival multifunctional
protein. Drug and radiation resistance of tumor tissues have been linked to
increased APE1 expression (165,210-213).
APE1 is post-translationally modified by phosphorylation, acetylation, and
ubiquitination (115,214-219). APE1 was found to be ubiquitinated by MDM2
(220,221), the major p53 regulator (222,223). However, APE1 ubiquitination was
later observed in mouse embryonic fibroblast defective of MDM2 (220), implying
existence of backup activities for APE1 ubiquitination other than MDM2.
Meisenberg et al. identified UBR3 as another E3 ubiquitin ligase for APE1 (224).
Properly maintained mitochondrial membrane potential is critical to meet
cellular energy demands through oxidative phosphorylation. Electron leaks from
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the respiratory chain complexes result in the generation of superoxide (O2-). The
mitochondrial superoxide dismutase is extremely efficient in scavenging O2- (225),
and thus cells at normal growth conditions maintain the oxidative stress at a
manageable level. This status quo may be broken by exogenous reagents,
genotoxic stresses, and gene mutations that impair mitochondria (226-228).
Damaged mitochondria elevate intracellular reactive oxygen species (ROS), and
result in further impairment of mitochondria (229). To avoid this vicious cycle, a
salvaging process named mitophagy is initiated to break down damaged
mitochondria and generate new mitochondria (230). It is becoming apparent that
mitophagy is modulated by DNA damage responses. Recent studies found that
activation of poly (ADP-ribose) polymerase 1 (PARP1) by DNA strand breaks plays
a pivotal role in the energy metabolism (231,232). In the process of DNA repair,
oxidative DNA damage are converted to DNA strand breaks as intermediate
lesions (233). The suppression of mitophagy by the activated PARP may be a selffeedback system during the repair of endogenous DNA damage. However,
understanding the interplay among factors for mitophagy and DNA repair proteins
is far from complete.
During mitophagy, proteins in damaged mitochondria are degraded via
polyubiquitination, which is mainly carried out by Parkin, a RING domaincontaining E3 ubiquitin ligase (234). PINK1 (PTEN-induced-kinase 1) is a critical
activator of Parkin (230,234). PINK1 phosphorylates ubiquitin and Parkin (235)
(236-238) and recruits Parkin from cytoplasm to mitochondrial surfaces to facilitate
ubiquitination of its target proteins such as mitofusin 2 (Mfn2), Miro, and VDAC1
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(239,240). Mutations in the Parkin and the PINK1 genes cause mitochondrial
degeneration and are associated with Parkinson’s disease and glioblastoma
(GBM) (230,241,242).
Considering that Parkin expression is induced by p53 (243,244) which
enhances APE1 ubiquitination (221), it is possible that Parkin ubiquitinates APE1.
Moreover, a recent proteomics study for identifying Parkin's substrates and
interacting proteins revealed APE1 as one of possible targets of Parkin (245).
These observations prompted us to investigate the activity of Parkin for APE1
ubiquitination. In this study, we investigated functional and physical interactions
between APE1, Parkin, and PINK1.
3.3

Materials and Methods

3.3.1 DNA, Cell Culture And Transient Transfection
All cDNAs in plasmid expression vectors used in this study are of humans.
Expression vectors for YFP-Parkin (23955) and cMyc-PINK1 (13314) (246,247)
were obtained from Addgene. Non-tagged wild-type (wt) PINK1 was then cloned
by PCR amplification into pcDNA3.1 (Invitrogen). The full-length human Parkin and
its specific E2 ligase UbcH7 were cloned for this study by PCR cloning from quick
cDNA clone (Clontech) using Phusion Taq DNA polymerase (NEB) with
appropriate

primers synthesized

(Integrated

DNA Technology)

into

the

pcDNA3.1Zeo (+) expression vector (Invitrogen). Mutations (R275W and C431F in
Parkin and G309D in PINK1) were introduced by PCR subcloning. The pBi16, a
mammalian expression vector with a flippase recognition target (FRT) site and a
doxycycline (Dox) inducible-dual promoter (248), is a generous gift from Dr.
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Grabczyk. The human Parkin and PINK1 cDNAs were cloned into pBi16 (named
pBi16-PaPi, Figure 3-1) for inducing both proteins together with doxycycline. All
sequences of DNA amplified by PCR were confirmed by DNA sequencing (ACGT
Inc. and GenScript Inc).
MEFla, a mouse embryonic fibroblast cells, deficient in mouse Ape1
(mApe1) and expressing hAPE1 was described previously for its extremely low
APE1 expression (122). The MEFla cells were cultured in DMEM High Glucose
medium (Hyclone) supplemented with 10% fetal bovine serum (Gemini Inc.), 1%
penicillin/streptomycin,

1%

L-glutamine

(Hyclone).

SH-SY5Y

(a

human

neuroblastoma) and A549 (a human lung adenocarcinoma) were purchased from
ATCC. The HEK293 derivative T-Rex 293 was purchased from Invitrogen. The TRex 293 cells were transfected with pBi16-PaPi and pOG44 expressing flippase
(Flp). 293/pBI16-PaPi (293-PaPi) stable transfectants were selected with 150µg/mL hygromycin. The 293-PaPi cells were plated on 60 mm dishes (1x106/dish).
After overnight incubation, Parkin and PINK1 were induced with 2 µg/mL
doxycycline. At the same time, drugs indicated in the results were added in the
culture medium, and together incubated for 16 hours. Cells were then harvested
for immunoblot analyses.
For transient transfection, cells were plated on 60 mm dishes at 4x105 1x106 and incubated for overnight. Lipofectamine 2000 (Invitrogen) was used for
transfection using OptiMEM-I (Invitrogen) with the vendors’ manual. PINK1 siRNA
was purchased from Applied Biosystems. Introduction of siRNA was standardized
for minimum cytotoxicity as the following method. Semi-confluent SH-SY5Y cells
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were suspended in the DMEM medium at 1x107 cells/mL, and mixed with 200 nM
siRNA. Cell/siRNA suspensions in 0.1 cm cuvettes were then electroporated using
ECM 830 square wave electroporation system (BTX) at 920V, 120 µF, 2 pulses at
0.1 sec interval. After 15 minutes at room temperature, cells were transferred to
100 mm dishes (Corning) containing complete DMEM-High Glucose media
(Gibco) and incubated for 72 hours. When necessary, 10 µM carbonyl cyanide 3chlorophenylhydrazone (CCCP) was added after 48 h, and further incubated for
24 hours (total 72 hours after the electroporation). Cells were then harvested and
examined with immunoblot.
3.3.2 Immunoblot (Western blot) assay
Whole cell extracts were prepared from cells detached by scraping after
being washed with PBS twice, and resuspended in RIPA buffer (249)
supplemented with proteinase inhibitor cocktail (Roche) and 40 µM MG132. After
adjusting protein concentration, the extracts were run in 10% acrylamide SDSPAGE, transferred to PVDF membrane (Bio-Rad), and blotted with appropriate
antibodies. SDS-PAGE samples were run with a pre-stained protein size marker
(NEB, P7709).

129

Figure 3-1: Dual expression vector pBi16-PaPi
The human Parkin and PINK1 cDNA were cloned into pBi16 [1] and stably
integrated using FRT site-directed recombination in the T-Rex 293 cells by
hygromycin B (HygB) selection (Invitrogen). pCMV*: doxycycline-inducible CMV
promoter; pOG44: Flp site-specific recombinase expression vector (Invitrogen).

130

3.3.3 Detection of Ubiquitinated APE1 in A549
Histidine hexamer-tagged ubiquitin (6xHis-ub) cDNA was transfected with
APE1, Parkin, and PINK1 in A549 cells and incubated for 24 hours. The cells were
lysed in the binding buffer (20 mM Tris pH 8.0, 0.5 M NaCl, 0.1 % NP-40, 10 mM
imidazole) with 40 μM MG132 (Sigma) and proteinase inhibitor cocktail without
EDTA (Roche). The crude cell extracts (total fraction) were incubated with Ni-NTA
magnetic beads (Qiagen) for 15 minutes at 4 ̊C, washed with the binding buffer,
and eluted with binding buffer with 120 mM imidazole. The total and eluted (Histagged protein-enriched) fractions were analyzed by immunoblot using anti-APE1
antibody.
3.3.4 Analysis of Localization of YFP-Parkin and APE1
MEFla cells were spread on coverslips a day before DNA transfection. The
cDNA carrying YFP-Parkin and APE1 were co-transfected in the same way as
described above, and incubated for 24 hours. If necessary, MG132 was added and
incubated. Cells were incubated in the presence of Mitotracker Red (Invitrogen),
fixed in 3.7% formaldehyde, and then permeabilized in PBS containing 0.2%
TritonX-100 for 15 minutes. After washing with PBS twice, cells were blotted with
anti-APE1 antibody, stained with anti-mouse IgG antibody conjugated to Alexa
Fluor 488 (Invitrogen) followed by DAPI staining, and mounted on glass plates with
Vector Lab mounting reagent. Cells were then analyzed with Leica TSP SP5
Confocal Microscope confocal microscopy at the Imaging Core facility of University
of Kentucky.
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3.3.5 Co-Immunoprecipitation (CO-IP) of Recombinant APE1-FLAG and
Parkin
E. coli BLR (DE3) strain (EMD Biosciences) was transformed with a pRSFDuet1 derivative (EMD) carrying Parkin and either of APE1-FLAG or APE1
(negative control) cDNAs. The cells were grown until OD600 reached 0.6 to 0.8,
and then expressions of the proteins were induced with 0.5 mM IPTG (Fisher) at
16˚C for 16 hours (220,250). Cells were lysed in a co-IP buffer (120 mM NaCl,
2mM EDTA, 0.1mM EGTA, 0.05% NP40, 1 mM DTT, 50mM HEPES pH 7.9)
supplemented with proteinase inhibitor cocktail (Complete Ultra Mini, Roche). After
centrifugation for 20 minutes at 4˚C, small portions of supernatants were kept
separately as total fractions (inputs), and the remaining samples were subjected
to immunoprecipitation with agarose resin conjugated to the anti-FLAG antibody
M2 (Sigma). The resin was washed in the co-IP buffer, and eluted in 100 µg/mL
FLAG peptide (Sigma), and both total and IP fractions were analyzed by
immunoblotting using anti-APE1 and anti-Parkin antibodies.
3.3.6 Proximity Ligation Assay (PLA)
A549 cells were spread on coverslips and incubated for overnight before
transfection of the APE1 and Parkin cDNA. The cells were then incubated with 1
μM Mitotracker RED for 1 hour and fixed in 100% methanol at -20˚C and then in
100% ice-cold acetone.
The samples were processed according to the OLINK Bioscience DuoLink In
Situ protocol. Briefly, the coverslips were rehydrated in PBS (pH7.5) containing
0.1% Triton X-100 (v/v) for at least 30 minutes at room temperature. The samples
were then blocked with 5% BSA in PBS+ Triton X-100 for 30 minutes. The primary
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antibodies were applied (1:200 ms-anti-parkin, 1:250 rb-anti-APE1) and incubated
overnight at 4°C in a humidity chamber; all other incubations were carried out in a
37°C humidity chamber unless otherwise noted. The samples were washed and
incubated with the Duolink secondary antibodies (anti-mouse and anti-rabbit IgG)
for 1 hour. After washing, the samples were incubated with the ligation reaction
mixture for 30 minutes, washed, and then further incubated with the green
amplification reagent for 90 minutes. After the final wash, the samples were
mounted with Duolink In Situ mounting medium containing DAPI. The fluorescent
signals in the cells were analyzed using an Olympus inverted fluorescence
microscope.
3.3.7 Tissue Extract Preparation
Snap-frozen GBM specimens were obtained from male patients (50-75
years old) in accordance with IRB regulations. Whole cell lysates of the tissues
were prepared using the Fisher Cryo-homogenizing system. Briefly, the samples
were disaggregated through grinding with a clean pre-chilled mortar and pestle.
The samples were then transferred to a micro-centrifuge tube and RIPA buffer,
containing 40 μM MG132 and protease inhibitors, was added to an approximate
concentration of 10 mg/μL pre-ground weight. The samples were then centrifuged
to collect large debris, and the supernatant was used to prepare a stock in SDSPAGE loading buffer and to determine final protein concentration. The SDS-PAGE
stock was sonicated and incubated at 70° C for 5 minutes and stored at -80° C
until use. Before SDS-PAGE, the samples were diluted to a final concentration of
3 μg/μL in SDS-PAGE loading buffer.
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3.3.8 Immunohistochemistry for GBM and Control Tissues
A combined total of 17 GBMs and control brain tissues were obtained from
the Markey Cancer Center Biospecimen and Tissue Procurement Shared
Resource Facility (BSTP SRF). Formaldehyde-fixed paraffin embedded 5 μm
sections were deparaffinized in xylene and rehydrated stepwise using graded
ethanol and finally water. Dako antigen retrieval buffer was used with a Biocare
Medical decloaking chamber for antigen retrieval following the manufacturer’s
protocol. Dako peroxidase blocking reagent was used to inhibit endogenous
peroxidase activity. Sections were incubated with primary antibody for 1 hour at
room temperature: APE1, Parkin. Next, sections were incubated with polymer
linked secondary antibody, either mouse (Dako K4007) or rabbit (Dako K4003) for
30 min at room temperature followed by development with diaminobenzodine.
Following washing, slides were counterstained with Meyer’s hematoxylin and
allowed to Blue in ammonia water before dehydration in graded ethanol. Slides
were incubated in xylene before affixing coverslip.
High-resolution digital image slides of GBM and control brain tissue were
obtained by scanning with the Aperio ScanScope (Leica) at 20x magnification.
Aperio ImageScope software V 11.2.0.780 and the software’s algorithms for
Positive Pixel Count V9 and Nuclear V9 were used to analyze these images for %
total intensities for APE1 and Parkin in tissue and nuclear localization respectively.
3.3.9 Chemicals and Other Reagents
CCCP and MG132 were purchased from Sigma. Antibodies used in this
study are those for APE1 (Santa Cruz, sc-55498), PINK1 (Novus BC100-494 and
Protein Tech 23274-1-AP), Parkin (Santa Cruz, sc-32282), β-tubulin (Santa Cruz,
134

sc58884), GAPDH (Invitrogen, AM4300), p53 (Santa Cruz, sc-126). Pre-stained
protein molecular weight marker was purchased from New England Biolab
(P7709).
3.4

Results

3.4.1 Direct Involvement of Parkin in APE1 ubiquitination
To test whether APE1 is ubiquitinated by Parkin, protein extracts from A549
expressing histidine hexamer-tagged ubiquitin (His-Ub), APE1, Parkin and PINK1
were subjected to enrichment of His-Ub through nickel resin purification (251).
Monoubiquitinated as well as polyubiquitinated APE1 were detected in the His-Ub
enriched fraction when Parkin was expressed (Figure 3-2 A lane 2 vs. lane 1).
The results indicated Parkin was capable of ubiquitinating APE1. The His-Ub
diminished when PINK1 was co-expressed while intact APE1 decreased (lane 3
v.s. lane 4), suggesting that PINK1 was required for polyubiquitination and
degradation of APE1.
To understand functional requirements of Parkin and PINK1 for APE1
ubiquitination, a mouse embryonic fibroblast cell line MEFla (MEFlowAPE1) was
transiently transfected with Parkin, PINK1, and APE1. APE1 levels were not
altered when either Parkin or PINK1 was expressed alone (Figure 3-2 B lanes 3
and 4 v.s. lane 2) (122). However, expressing both Parkin and PINK1
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Figure 3-2: Functional requirements for APE1 ubiquitination
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(A) Detection of monoubiquitinated and polyubiquitinated APE1. A549 was
transfected with APE1 (lane 1), APE1 and Parkin (lane 2), His-tagged Ubiquitin
(His-Ub), APE1, and Parkin (lane 3), His-Ub, APE1, Parkin, and PINK1 (lane 4).
Total protein lysates and eluted fractions (enriched with His-Ub) were analyzed
with APE1 antibody as described in Materials and Methods. (B) MEFla transfected
with 1: empty vector, 2: APE1, 3: APE1 and PARKIN, 4: APE1 and PINK1, 5: APE1,
PINK1, and PARKIN, 6: APE1, PINK1, PARKIN with 10 μM MG132 for 6 hours. (C)
MEFla transfected with APE1, PCNA, p53 without (ctrl) or with Parkin and PINK1
(PaPi) and the stabilities of APE1, PCNA, p53 were monitored after 24 hours. (D)
Mutant Parkin (275 = R275W, 431 = C431F) and PINK1 (309 = G309D) were cotransfected in MEFla as shown in the table. Protein levels were examined after 24
hours incubation. MG132 was at 3 µM for 16 hours. (E) The WT (full-length) or
ND20 (N-terminal 20 a.a. truncation) APE1 was co-transfected with Parkin and
PINK1 in MEFla. Lane 6: MG132 was added at 3 µM for overnight incubation.
Expression of PINK1 in lanes 3 and 5 was confirmed separately from lane 6 which
otherwise caused a halo effect. (F) ND41 (41 a.a. N-terminal truncation) APE1 was
examined after Parkin and PINK1 expression.
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caused a marked APE1 decrease (Figure 3-2 B lane 5; also in Figure 3-2 D lane
3, Figure 3-2 E lane 3E, and Figure 3-2 F lane 2). p53 is a well-known target of
ubiquitination by other E3 ubiquitin ligases (252-254). We tested whether p53 was
also efficiently ubiquitinated by Parkin. However, the stability of p53 was unaffected
by Parkin and PINK1 (Figure 3-2 C). Similarly, proliferating cell nuclear antigen
(PCNA), highly susceptible to mono- and poly-ubiquitination (254), was not
modified by Parkin (Figure 3-2 C). The unaltered stabilities of p53 and PCNA as
well as β-tubulin and β-actin indicated a high specificity of the reaction of Parkin
on APE1. Incubating cells with a 26S proteasome inhibitor MG132 restored the
APE1 level (Figure 3-2 D, lane 4 v.s. lane 3).
The Parkin polypeptide contains two RING domains (Figure 3-3). R275W
and C431F missense mutations, which are located in the first and second RING
domains in Parkin respectively (Figure 3-3), abrogate its E3 ligase activity and
cause early onset Parkinson’s disease (255,256). These Parkin mutants failed to
degrade APE1 (Figure 3-2 D lanes 5 and 9; Table 3-1). PINK1 carrying G309D
missense mutation is defective in its kinase activity (Figure 3-3), and incapable of
activating Parkin (247,255,257). The G309D PINK1 did not activate APE1
degradation (Figure 3-2 D lane 6; Table 3-1). These results suggested that the
ligase activity of Parkin was required for APE1 degradation, for which the kinase
activity of PINK1 was also critical.
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Figure 3-3: Parkin, PINK1, and APE1 Functional Domains
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3.4.2 Interaction of APE1 with Parkin
Sarraf et al. recently identified proteins interacting with Parkin and their
possible ubiquitination sites, and APE1 was found to be a protein interacting with
Parkin through its N-terminal segment, i.e., 20-30th amino acids from N-terminus
(245). To probe the importance of the N-terminal region of APE1 for the stability,
MEFla cells were transiently transfected with N-terminally truncated APE1, ND20
and ND41 (N-terminal 20 and 41 amino acids deletions), along with Parkin and
PINK1. While ND20 APE1 was efficiently degraded by Parkin (Figure 3-2 E and
Table 3-1), ND41 APE1 was significantly more resistant to Parkin dependent
degradation compared to those of the full-length and ND20 APE1 (Figure 3-2 F
and Table 3-1). It is likely that APE1 is mainly ubiquitinated at the amino acid
residues 20-41 which contains two Lys clusters (24K-25K-27K and 31K-32K-35K),
which is consistent with the previous studies showing that the N-terminal residues
contained major ubiquitin acceptor Lys residues catalyzed by MDM2 and UBR3
(221,224).
In the normal condition, APE1 in MEFla was localized predominantly in the
nuclei (Figure 3-4 A, control). When the cells were treated with MG132,
cytoplasmic APE1 was visibly increased 3 hours after the treatment, and became
indistinguishable from the nuclear APE1 after overnight incubation of the cells with
MG132 (Figure 3-4 A). The major fraction of Parkin is present in the cytoplasm
(240).
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Table 3-1: Effect of Parkin and PINK1 on the stability of APE1

Relative APE1 intensities (%) in MEFla with the wild-type or mutant Parkin and
PINK1 expressions were calculated by comparing with those without Parkin nor
PINK1. aAPE1 amounts were normalized by β-tubulin, and compared with that
without Parkin and PINK1. Values based on more than three independent
experiments.

bP

values by Student's t-test. Each value (more than three

experiments) calculated with the result of the first row (with wt-APE1, wt-Parkin,
and wt-PINK1).

141

Figure 3-4: Interaction of APE1 with Parkin in the cytoplasm
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(A) Accumulation of APE1 in the presence of MG132. MEFla cells expressing the
wild-type APE1 were incubated with MG132 for indicated time periods. MG132
concentrations were 40 µM (0 - 3 hours) and 3 µM (overnight). APE1 was labeled
with anti-APE1 antibody and AlexaFluor 488 and analyzed in fluorescence
microscopy. (B) MEFla transfected with APE1 and YFP-Parkin were incubated with
MG132 40 µM for 3 hours, fixed, labeled with anti-APE1 and AlexaFluor 633
(shown in purple), and then analyzed by confocal microscopy. Z-series pictures
were taken for a detailed analysis (Figure 3-5). (C) Proximity ligation assay (PLA)
between APE1 and Parkin in A549. A549 expressing APE1, Parkin, PINK1 as
indicated. APE1 and Parkin specific antibodies were used to probe the interactions
of the two proteins as described in Materials and Methods. Positive signals were
seen only in the cells co-transfected with APE1, Parkin, and PINK1 (bottom panel
shown with arrows). MT: fluorescent signals by MitoTracker Red (Invitrogen). (D)
Co-immunoprecipitation of APE1 and Parkin. Parkin and APE1 (lane 1) or Parkin
and APE1-FLAG (lane 2) co-expressed in E. coli BLR were subjected to
immunoprecipitation using FLAG antibody, and the total and eluted fractions were
analyzed in immunoblot using APE1 and Parkin antibodies.
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Figure 3-5: Colocalization of YFP-Parkin and APE1
MEFla cells were transfected with YFP-Parkin and APE1, and incubated in 40 µM
MG132 for 3 hours Cells were then stained with MitoTracker Red, anti-APE1 and
anti-IgG-AlexaFluor 633, and then analyzed by confocal microscopy (Leica) to
analyze co-localization of YFP-Parkin and APE1. Colors in Merged pictures: red:
MitoTracker Red, green: YFP-Parkin, blue: APE1. Z-series photographs showing
co-localization of YFP-Parkin and APE1.
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The possibility of cytosolic co-localization of APE1 with Parkin was
elucidated, using YFP-Parkin and APE1. After MG132 treatment, APE1 was found
to be co-localized with YFP-Parkin in the cytoplasm (Figure 3-4 B and Figure 31). The cytoplasmic co-localization of APE1 and YFP-Parkin suggested that the
physical interaction occurred in the cytoplasm. This possibility was examined with
proximity ligation assay (PLA) (233). Antibodies specific to APE1 and Parkin were
used to label the two proteins and signals were detected when the two proteins
were in the proximate location to each other (Figure 3-4 C). The PLA signal was
detected when APE1 and Parkin were co-expressed. Importantly, the PLA was
observed mainly in the cytoplasm but not in the nuclei or inside of mitochondria.
The absence of Parkin-APE1 interaction in the nuclei is consistent with the
cytosolic localization of Parkin in previous studies (258-260). To test whether APE1
directly interacts with Parkin without involvement of other cellular factors such as
ubiquitin or PINK1, recombinant Parkin was expressed with APE1 or with FLAGAPE1 simultaneously in E. coli, and performed FLAG-immunoprecipitation to
detect Parkin in the FLAG-APE1 enriched fraction. Parkin was specifically detected
in the FLAG-APE1 containing fraction (Figure 3-4 D). The result indicated that
APE1 directly interacts with Parkin. Co-immunoprecipitation of Parkin by ND41
APE1-FLAG was significantly decreased (Figure 3-6) compared to that by fulllength APE1, indicating that the N-terminal segment is pivotal for the interaction.
However, it should be noted that Parkin signal was not completely disappeared in
the ND41-FLAG IP fraction, and we

145

Figure 3-6: APE1 and Parkin Interaction
Interaction of full-length and ND41 APE1 with Parkin. Parkin and APE1-FLAG, or
Parkin and ND41 APE1-FLAG, were co-expressed in E. coli BLR, and FLAG
immunoprecipitation was carried out as described in the Materials and Methods.
Ratios of [Parkin]/[APE1] in the IP fraction was determined using the signal
intensities. Relative ratios for the full-length APE1 versus ND41 APE1 was
2.61±0.62 p < 0.5). Total 3 immunoprecipitation experiments were carried out to
determine the mean and standard deviation.
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could not exclude the possibility that the downstream APE1 polypeptide is also
involved in the interaction of APE1 with Parkin.
3.4.3 Ubiquitination and Degradation of Endogenous APE1 by Parkin and
PINK1
To examine the effect of Parkin expression on endogenous APE1, a lung
adenocarcinoma cell line A549 was transiently co-transfected with Parkin and its
cofactors (255,261-264), namely, Uba1 (E1 ligase), UbcH7 (Parkin-specific E2
ligase), and PINK1 (Figure 3-7 A). The level of endogenous APE1 decreased in a
does-dependent manner (Figure 3-7 B). Densitometry of the immunoblot revealed
that the level of the endogenous APE1 was down to 60% of the control cells
transfected with the vector plasmid DNA alone.
Levels of the endogenous p53 and PCNA as well as housekeeping proteins
β-tubulin and GAPDH were unaltered by the expression of Parkin and its cofactors
(Figure 3-7 B). These results indicated a high specificity of the reaction of Parkin
on APE1, consistent with the results with the ectopically expressed proteins
(Figure 3-7 C). Total protein extracts from A549 were analyzed for ubiquitination
of endogenous APE1. A specific band appeared at the position for
monoubiquitinated APE1 after cells were transiently transfected with Parkin
(Figure 3-2 C). Therefore, endogenous APE1 was ubiquitinated and degraded by
Parkin.
Inducible expression of Parkin and PINK1 without transient transfection
would provide a more refined experimental condition. To achieve this, a derivative
of HEK 293 cell line 293-PaPi was used. The 293-PaPi is a stable transfectant of
HEK293, and enables simultaneous induction of Parkin and
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Figure 3-7: Parkin targets APE1 for degradation
(A) Expression of Parkin and its cofactors, Uba1, UbcH7, Parkin and PINK1 in
A549. A549 was transfected with (-) empty vector alone or (+) the vectors carrying
Parkin, PINK1, Uba1, and UbcH7 cDNAs. β-tub: β-tubulin. Note that there was no
change in the Uba1 probably due to its abundance. (B) A549 cells were transfected
with cDNA expression vectors for ubiquitin, UBA1, UBCH7, Parkin, and PINK1.
Amount of each DNA: 1: 0 µg, 2: 0.17 µg, 3: 0.35 µg, 4: 0.7 µg. Empty vector DNA
(vec) was added to each to make the total amount of DNA equal among samples.
Cells were then incubated for 16 h, and harvested for immunoblot examination. (C)
A549 transfected with vector alone (1) or ubiquitin, Uba1, UbcH7, Parkin and
PINK1 as in (B) and incubated with MG132 (3 μM for 16 hr), and APE1 (middle)
and its ubiquitinated forms (top), as well as β-tubulin (bottom) were analyzed by
immunoblot separately.
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PINK1 by doxycycline from a bidirectional promoter (248) (Figure 3-1). Induction
of Parkin and PINK1 (Figure 3-8 A) did not alter APE1 or β-tubulin while Mfn2
decreased clearly (Figure 3-8 B). Because Parkin's E3 ligase function is active at
mitochondria, the 293-PaPi cells were treated with H2O2 to increase APE1 in
mitochondria(265). Treatment of the cells with H2O2 decreased APE1 to
approximately 70% of the control while the amount of β-tubulin was still unchanged
(Figure 3-8 B). Although the change of APE1 level by H2O2 in the doxycyclinetreated 293-PaPi was statistically significant, doxycycline or H2O2 alone did not
show significant difference from the untreated control cells (Figure 3-8 B). These
results indicated that degradation of APE1 by Parkin was limited compared to the
transiently expressed APE1, suggesting that a large portion of APE1 is not in
contact with the Parkin and PINK1 without induction of stresses such as oxidative
stress.
3.4.4 Loss of Parkin is associated with elevated APE1 levels in GBM
Parkin deficiency has been associated with GBM (241,242). To elucidate
the correlation between Parkin and APE1 in brain tumors, expression levels of
Parkin and APE1 in both GBM and non-neoplastic brain tissues were examined.
Qualities of the monoclonal antibodies for Parkin and APE1 were confirmed in
Western blot to detect the corresponding proteins specifically (Figure 3-9 A).
Interestingly, the GBM tissues showed increased APE1 levels while decreasing the
Parkin levels (Figure 3-9 A). Parkin and APE1 levels were examined in detail by
immunohistochemistry (Figure 3-9 B). Parkin levels in the non-neoplastic brain
tissues were higher than those of GBM tissues (Figure 3-9 C, p = 0.0009),
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Figure 3-8: Effect of Parkin and PINK1 co-expression on APE1
(A)

Parkin and PINK1 expressions examined in 293-PaPi cell lysates after 16

hours of treatment without (lane 1) or with (lane 2) doxycycline (2 µg/mL). (B) (Top)
Immunoblot for APE1, Parkin, Mfn2, and β-tubulin levels in 293-PaPi cells treated
with doxycycline for 16 hours. CCCP: 10 µM; H2O2: 50 µM. (Bottom) Averages of
APE1/β-tubulin ratios with the treatments as indicated. *p < 0.05. (C) SH-SY5Y
cells were incubated with DMSO only (-) or with 10 µM CCCP (+), and incubated
for 24 hours at 37˚C and analyzed by immunoblot. In the right panel, SH-SY5Y
cells were differentiated by the 5-days treatment with 10 µM retinoic acid (RA), and
then incubated with 10 µM CCCP for 24 hours. (D) Scrambled control (lanes 1 and
2) or PINK1 siRNA (lane 3) were electroporated in SH-SY5Y, and the level of APE1
was examined after 72 hours incubation with 24 hours treatment of DMSO (lanes
1 and 3) or 10 µM CCCP (lane 2).
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Figure 3-9: Parkin and APE1 expressions in GBM
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(A) Five glioma and one non-neoplastic (from epilepsy surgery) brain tissues were
processed for protein extraction and analyzed in immunoblot assays. (B)
Representative results of immunohistochemistry from non-neoplastic (Control) and
GBM tissues. Magnifications: 1x, 5x, and 20x. (C) Total levels of APE1 (Left panel)
and Parkin (Middle panel) were measured and normalized by nuclear counts using
Aperio analytical software (Leica), and are shown as box plots for the nonneoplastic (N) and GBM brain tissues. (Right panel) Parkin levels were divided
by APE1 levels of the corresponding tissues, and the calculated ratios are plotted.
Each box plot shows the median value (bold horizontal line), the first and third
quartile (box), and 1.5x interquartile range (whiskers). Individual values are also
shown as circles. The p values (Student's t-test) are 0.009, 0.0025, 0.0013 for the
left, middle, and the right panel, respectively.
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while APE1 signals were higher in GBM tissues than the non-neoplastic tissues (p
= 0.0025). Parkin/APE1 ratios were calculated, and were significantly lower in the
GBM tissues than in the non-neoplastic brain tissues (Figure 3-9 C, p = 0.0013).
Notably, the variance of Parkin/APE1 ratios was significantly lower than that of
either APE1 or Parkin levels, implying that the loss of Parkin and the gain of APE1
expression during the tumorigenesis are associated with each other.
3.5

Discussion
APE1 is primarily known for repair of oxidized and alkylated DNA damage,

but also is an important gene expression regulator that activates transcription
factors such as AP-1 and NFκB (119). Both APE1 functions are pro-proliferation
and advantageous to cell survival, which explains elevated APE1 expression in
tumor tissues. Indeed, tumor cells with high APE1 levels acquire drug and radiation
resistance (165,210-213). Therefore, identifying factors that control APE1 levels
should provide information relevant to the cancer therapeutics, particularly those
causing cytotoxicity via DNA damage generation.
We speculated a possible role of Parkin for controlling intracellular levels of
APE1, because (1) backup E3 ligase activity was detected in cells defective in
MDM2 (220), (2) Parkin is induced by p53, and (3) a proteomics study detected
APE1 as a possible substrate of Parkin (243-245). The present results show that
Parkin is a quite efficient and highly specific E3 ligase to ubiquitinate APE1. The
examination of mutant Parkin and PINK1 supports that the ubiquitination reaction
is dependent on the E3 ligase activity of Parkin and the kinase activity of PINK1.
Evidence for the direct interaction of APE1 with Parkin was obtained with co153

immunoprecipitation of APE1 and Parkin and by proximity ligation assay. Based
on these results, we conclude that Parkin directly ubiquitinates APE1. While
monoubiquitinated APE1 was readily detected by MDM2 and UBR3 (221,224),
detection of monoubiquitinated APE1 catalyzed by Parkin and PINK1 was
relatively difficult. This observation implies that monoubiquitinated APE1
immediately undergoes polyubiquitination process by Parkin, and APE1 is
efficiently degraded after the reaction by Parkin. Inhibiting the 26S proteasome by
MG132 resulted in increase of monoubiquitinated APE1 in a manner dependent
on Parkin and PINK1. Thus, Parkin with its cofactors Uba1, UbcH7, and PINK1
ubiquitinates directly, and degrades APE1 through 26S proteasome more
efficiently than those processed by MDM2 and UBR3.
While ND20 APE1 (N-terminal 20 a.a. truncation) was degraded by Parkin
as effectively as the full-length APE1, the stability of ND41 APE1 in the presence
of Parkin and PINK1 was significantly increased. The results indicated that the Nterminal polypeptide between 20 to 40 amino residues in APE1 is important for the
Parkin-dependent ubiquitination.
The N-terminal 60 amino acid segment in APE1 is not defined well
functionally and structurally. This domain is unique in the mammalian AP
endonuclease (266), and is dispensable for the AP-endonuclease activity (267),
and thus it has been speculated that the N-terminal domain has an
uncharacterized function unique to mammalian cells. In this context, it is interesting
that the segment is rich in Lys, the major acceptor for acetylation and
ubiquitination. The N-terminal segment between 20 and 41 amino acid residues
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contains six Lys residues, namely, 24K, 25K, 27K, 31K, 32K, and 35K. Acetylation
of APE1 at these Lys residues was reported (39,215,219,268). These N-terminal
Lys residues were also the main ubiquitin acceptors for MDM2 and UBR3 E3
ligases (221,224). Based on a recent quantitative proteomics study, the APE1
segment 18-RTEPEAKKSKTAA-30, containing Lys 24, 25 and 27, was identified
to be a possible target of ubiquitination catalyzed by Parkin (245). Therefore, Lys
residues in the N-terminus may be essential for the post-translational modifications
that modulates APE1's gene regulatory function (39) and for altering its stability by
polyubiquitination.
Although activating Parkin resulted in decrease of endogenous APE1 in
three cell lines, SH-SY5Y, A549, and 293-PaPi, it should be noted that Parkin was
active on endogenous APE1 only when stressful conditions (CCCP and H2O2)
were invoked. We speculate that the modest effect of Parkin on endogenous APE1
is due to the fact that the majority of endogenous APE1 is compartmentalized in
the nuclei, which may prevent Parkin from reacting on APE1. Stresses induced in
the cells activated Parkin system (CCCP in SH-SY5Y) or facilitated mitochondrial
localization of APE1 from nuclei (H2O2 in 293) (265). Although endogenous APE1
significantly decreased in A549 without any treatments, transient transfection is
known to induce stress responses (269,270). Thus, APE1 ubiquitination by Parkin
is unique in that the main site of the reaction is the cytoplasm, which is supported
by the proximity ligation assay. In contrast, APE1 ubiquitination by MDM2 and
UBR3 occurred mainly in the nuclei (220,224). It should be noted that APE1 was
co-purified with mitochondria, but majority of this APE1 fraction was found to be on
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the surface of mitochondria (271), which is the major platform for the Parkin driven
protein degradation. However, it is highly plausible in the event of mitophagy, APE1
in the mitochondria becomes the target of Parkin as well.
Although APE1 has been studied for its activities in the nuclei, there is an
increasing interest in APE1‘s presence in the cytoplasm and its cancer-promoting
effect (109,272,273). Kakolyris et al. found that APE1 was present in the cytoplasm
of the normal human tissues (274). More recently, malignant cancer cells in the
lung exhibited cytoplasmic APE1 at unusually high levels, and was linked to a poor
prognosis of cancer treatment (109). Vascott et al. found that treatment of cells
with an APE1 inhibitor E3330 caused cytoplasmic translocation of APE1 (275).
Frossi also found that H2O2 induced translocation of APE1 into mitochondria (265).
These studies suggest a cellular mechanism to export APE1 from nuclei. Based
on these previous studies and present results, it is postulated that APE1
ubiquitination by Parkin is active in the cytoplasm, in which damaged APE1
proteins are ubiquitinated and degraded by Parkin to protect cells from undergoing
malignant transformation. Meanwhile, undamaged, properly folded APE1 in the
nucleus may be protected from this salvage system by the compartmentalization.
Originally identified as a gene of which deficiency is responsible for PD,
Parkin was recently reported as a tumor suppressor gene of which loss of
heterozygosity was frequently found in GBM (241). Analysis of Parkin and APE1
expressions in normal and GBM specimens revealed that Parkin/APE1 ratios
(expression of Parkin relative to that of APE1) in the GBM tissues were uniformly
low, while those in the non-neoplastic brain tissues showed much higher values
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and larger variance than those in GBM. This observation implies a correlation
between the loss of Parkin and the high expression of APE1 in the brain tumor
tissues. It is possible that a lack of Parkin activity either by loss of heterozygosity
or by p53 mutation may lead to deficiency in regular APE1 degradation, and may
accumulate in the cytoplasm as well as in the nuclei. However, the results do not
determine whether Parkin deficiency is the direct cause of high APE1 activities in
GBM, or vice versa. More recently, Hu et al. reported that melanoma specific
inactivation of the Parkin gene (276). According to the study, melanoma specific
Parkin alterations were observed at significantly high odds ratios over healthy
control tissues. The alterations included copy number variations, splicing
mutations, and putatively inactivating mutations including N273S, R275W, and
P437L which are adjacent to the missense mutations that cause early onset
Parkinson's disease (R275W and C431F). Further studies are necessary to
investigate whether Parkin is crucial for the tight regulation of the intracellular level
and subcellular distribution of APE1 to prevent cells from becoming malignant
tumors.
3.6
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Chapter 4:
4.1

Summary and Future Directions

Summary
Genetic alterations have long been linked to tumorigenesis. In the first

study, we discuss the discovery of potential biomarkers for head and neck cancer,
and a potential mechanism for how APE1 mediates inhibition of antioxidants and
tumor suppressors. In the second study, we discuss using TCGA transcriptome
database to identify genetic alterations between matched normal and tumor
tissues. In addition, we discuss the discovery of a dominant physical effect that
leads to synchronization of genes at the same chromosomal location. In the third
study, we identified that Parkin and PINK1 are necessary for ubiquitination and
degradation of APE1. The loss of Parkin was associated with aberrant APE1 in
glioblastoma multiforme.
4.1.1 Chapter 1 summary
The study in chapter 1 identified multiple, potential biomarkers for use in
HNSCC. Most importantly, we identified potential biomarkers in the early stages of
cancer that were associated with lymph node invasion, poorly differentiated
tumors, and decreased survival (Figure 1-7, 1-9, 1-10). This is important because
identifying patients with poor prognosis in the early stages of cancer allows the
best opportunity to prevent progression to invasive cancer. Biomarkers that predict
patient survival, and aggressive phenotypes may lead to improved patient survival.
By alerting physicians to patients at high-risk for worsened prognosis, treatment
strategies could be altered to improve patient survival. Additionally, identifying
these factors provides insight into novel treatment targets. Researchers are
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already exploring the use of APE1 inhibitors to overcome the treatment resistance
associated with APE1 overexpression (175).
We examined for differences in protein expression with regards to clinical
factors such as survival rates, presence of lymph node invasion, tumor grade, and
age at diagnosis. We identified reduced protein levels of antioxidant SOD3 in the
benign tissues in smokers, and in individuals with p16 positive tumors (Figure 19, 1-11, 1-12). Both tobacco usage and HPV are associated with increased
oxidative risk. Depletion of antioxidants likely led to increased oxidative stress and
cellular damage, which supported tumor development. We also observed that
individuals with increased SOD3 protein in benign tissue, typically developed
cancer later in life (Figure 1-13). Therefore, treatments that upregulate SOD3 in
individuals with depleted SOD3 may delay cancer development in high-risk
patients such as tobacco users.
In chapter 1, we examined possible mechanisms for how APE1
overexpression contributes to tumor development and treatment resistance.
Previously, APE1 gene expression has been linked to decreased gene expression
of tumor suppression DCN in mouse embryonic fibroblasts (122). Because loss of
DCN has been associated with increased metastasis and mortality, we examined
if and how APE1 suppresses DCN expression in HNSCC (124-132). Focusing on
APE1’s redox dependent transcriptional regulator activities, we examined the
relationship between APE1 and factors involved in antioxidant pathways including
NRF2, PPARGC1A, SOD2, and SOD3. Importantly, we identified that APE1
protein levels are significantly elevated in CIS. Overexpression of APE1 has been
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linked to genomic instability (109,110). Therefore, overexpression of APE1 in CIS
may lead to increased genomic instability, which allows CIS to progress to invasive
cancer. Though speculative, therapeutics that regulate APE1 levels may prevent
patients with early stage cancers from ever developing invasive cancer. We
identified a negative correlation between NRF2 gene expression and expression
of DCN, SOD2, and SOD3. In addition, we observed diminished SOD2 and SOD3
gene expression in cancerous tissues. Decreased expression of these important
antioxidants may lead to increased oxidative stress within tissues and in turn drive
further APE1 overexpression.
4.1.2 Chapter 2 summary
In chapter 2, we utilized TCGA transcriptome database to identify genes
that were coordinated synergistically with genes of the COP9 signalosome. The
COP9 signalosome is involved has been implicated in tumorigenesis. In particular,
the deneddylase activity of CSN5 regulates key proteins associated with cell cycle
control including tumor suppressor p53 (180).

Despite the COP9 signalosome

being studied, little is known about its role in normal tissues. Therefore, this study
examined COP9 signalosome gene coordination in matched normal and tumor
tissues to identify if gene coordination differs between normal and tumor tissues.
Analysis in normal tissues identified significantly coordinated expression of COP9
genes to that of genes involved in mitochondria-related functional pathways.
Because this coordination was lost in the matched HNSCC tissues, we speculated
that COP9 signalosome function is required for coordinated mitochondrial activity.
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The COP9 signalosome is also associated with regulating DNA repair
pathways. Although unpublished, observations made by the Izumi lab support a
functional link between APE1 and the COP9 signalosome as COP9 subunits were
found to interact with APE1. Additionally USP15, a deubiquitinase that is
associated with COP9, demonstrated a specific deubiquitinase activity on monoubiquitinated APE1. Recent studies found that COP9 can regulate nucleotide
excision repair (277,278). These observations including ours indicate that the
COP9 signalosome is an important cellular factor in the cellular stress response
and oncogenesis. This study highlights the usefulness of the transcriptome data of
the matched normal and tumor tissues accessible in TCGA, as the association of
COP9 genes and mitochondrial gene expression would not have been identified
using traditional cell culture systems.
Another unique knowledge we obtained in chapter 2, was the effects of
chromosomal location on gene expression correlation in tumor tissues. In this
study, highly synchronized to the COPS5 subunits were enriched in physical
proximity to the COPS5 gene had the highest correlation relative to the COP9
genes. This dominant chromosomal cis-effect on gene expression coordination
may be another mechanism by which gene expression becomes altered in cancer
tissues. Use of this technique may identify gene expression linkages that promote
tumor development and treatment resistance.
4.1.3 Chapter 3 summary
In chapter 3, we identified post-translational modification of APE1 by tumor
suppressor Parkin. As in other cancers, APE1 overexpression is linked to
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treatment resistance and increased mortality of patients with glioblastoma
multiforme (165,210,211). Parkin is a tumor suppressor and E3 ubiquitin ligase
(234). Ubiquitination of APE1 is critical for APE1’s function, and degradation (116).
Therefore, we hypothesized that Parkin’s E3 ubiquitin ligase function regulates
APE1 protein levels. In this study, we identified interaction between APE1 and
Parkin. We identified that Parkin along with PINK1, are needed for efficient APE1
degradation through post-translational modification. Using digital image analysis
of immunohistochemistry slides; we identified an inverse relationship between
Parkin and APE1 in glioblastoma multiforme (Figure 3-9). APE1 overexpression
in glioblastoma multiforme is linked to treatment resistance and increased mortality
(116). The loss of Parkin in glioblastoma multiforme likely prevents proper
degradation of APE1, contributing to APE1 overexpression. Therapeutics
increasing Parkin expression may restore normal ubiquitination and degradation
of APE1, which would normalize APE1 expression. Normalization of APE1
expression may restore treatment sensitivity and increase patient survival.
4.2

Future directions

4.2.1 Explore if APE1 gene has a dominant physical effect on the
transcription of nearby genes In HNSCC
In chapter 2, we identified a dominant cis-chromosomal effect of COP9
genes on transcription of nearby genes (153). Using TCGA transcriptome data
from tumor tissues, we identified that COPS5 gene expression was highly
correlated with genes in the same chromosomal region. This correlated gene
expression is thought to be a result of a dominant physical effect of the physical
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gene location. Therefore, we hypothesize that there is a chromosomal cis-effect
with genes located near APE1 and that this may upregulate expression of genes
that contribute to cancer development, and treatment resistance.
To examine the presence of a chromosomal cis-effect of genes having the
same chromosomal location of APE1, we employed techniques utilized in chapter
2. A preliminary examination was performed using TCGA transcriptome data from
matched normal and HNSCC tumor samples. This analysis revealed highly
correlated expressions of genes involved in DNA repair, and drug-resistance
relative to APE1. This correlation was observed in HNSCC tissues, but not in nonneoplastic tissues (Figure 4-1, Table 4-1). Multiple genes involved in DNA repair
were significantly correlated to APE1 in tumor tissues including poly ADP-ribose
polymerase (PARP2), SPT homolog facilitates chromatin remodeling subunit
(SUPT16H),

methyltransferase

like

3

(METTL3),

and

protein

arginine

methyltransferases (PRMT5) (Table 4-1). SUPT16H is involved in the chromatin
reorganization needed to allow DNA repair proteins to access DNA damage sites
(279). METTL3 and PRMT5 methyltransferases are involved in recruitment of DNA
repair factors to DNA damage sites (280,281). Therefore, these genes may
facilitate increased DNA repair capabilities and contribute to treatment resistance.
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Figure 4-1: Synchronized gene expression of genes involved in DNA repair
and cisplatin-resistance
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Pairwise plots were generated for DNA repair proteins APEX1 and SUPT16H, as
well as TOX4. The later of which is implicated in cisplatin-resistance. Genes are
located near 14q11. Data was obtained from TCGA for matched non-neoplastic
and HNSCC tumors (n=43).
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Table 4-1: Synchronization of DNA repair and survival genes physically
located near APE1 in HNSCC

Gene

Mbps

PARP2

-0.112

Correlation
Coefficient Relative
to APE1
NonTumor
neoplastic
-0.266

Role in
Repair

Reference

0.802**

BER, DSBR

Scott et al. 2014
(20)
Seibold et al.
2015 (283)

APEX1

0.000

1.000

1.000**

BER, Redox
gene
regulation

SUPT16H

0.896

0.171

0.845**

HR

Oliveira et al.
2014 (279)
Bounaix Morand
du Puch et al.
2011 (282)

TOX4

1.021

-0.113

0.743**

Cisplatinresistance

METTL3

1.043

-0.008

0.512*

NER

Xiang et al. 2017
(280)

PRMT5

2.465

0.322

0.639**

HR

Clarke et al. 2017
(281)

Correlation coefficients were generated for genes involved in DNA repair and cell
survival relative to APE1. Mbps: location in Chr 14 relative to APEX1. 42 matched
non-neoplastic and tumor tissues. Role in Repair: BER: DNA base excision repair;
DSBR:

DNA

double-strand

break

repair;

HR:

DSBR

via

homologous

recombination; NER: DNA nucleotide excision repair. *p < 1E-3 in; **p < 1E-6. No
genes in non-neoplastic tissues demonstrated statistically significant correlation.
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If APE1 overexpression induces expression of genes involved in DNA
repair, then cells may have enhanced DNA repair capabilities. This increased DNA
repair may minimize the DNA damaging effects of chemoradiotherapy, which is
necessary to kill tumor cells. In addition, we found that APE1 was significantly
correlated to TOX high mobility group box family member 4 (TOX4), which has
been implicated in cisplatin drug resistance (282). Cisplatin is commonly used in
the treatment of head and neck cancers.
Overexpression of APE1 has been linked to cisplatin resistance, which
contributes to poor patient outcome (284). The dominant chromosomal cis-effect
observed between APE1 and TOX4 may be one way that APE1 is contributing
towards treatment resistance (Table 4-1) (210). It is likely that tumors lose
coordinated gene regulation and that the chromosomal location becomes a
dominant factor in regulating gene expression. Newer research has established
that genes are encapsulated locally in a chromosomal conformation named
topologically associated domains (TADs) that consist of transcriptionally regulated
units (285,286). Alterations of TAD structures were associated with tumorigenesis.
Identifying TAD structures specific to HNSCC may identify tumors that are more
sensitive to certain cancer treatments, which could improve patient survival.
4.2.2 Assessing if APE1 increases NRF2 activity to promote
downregulation of DCN, and SOD3
In chapter 1, we originally hypothesized that APE1 suppressed DCN and
SOD3 indirectly through NRF2. The proposed model in this study is largely based
on correlative analysis of protein and gene expression data. This model could be
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more firmly supported by the addition of in vitro experiments including promoter
assays and chromatin immunoprecipitation. Despite a positive correlation between
APE1 and NRF2 protein expression, no correlation was observed between APE1
and NRF2 gene expression (Table 1-2, Table 1-3). However, APE1 is known to
interact with NRF2 and increase NRF2’s transcriptional regulatory activity (141).
APE1 may still modulate expression of DCN and SOD3 by increasing NRF2
activity. In chapter 3 we utilized the proximity ligation assay technique to detect
interaction between APE1 and Parkin in cell lines (116). This same technique can
be used in fixed tissues. To support our hypothesis that NRF2 interacts with APE1,
the proximity ligation assay in HNSCC tissue samples can be used to identify
interaction between APE1 and NRF2. Although APE1 and NRF2 physical
interaction supports that APE1 binds to NRF2 and potentially increases NRF2
activity, more direct in vitro assays are needed to confirm this. Using head and
neck cancer cell lines, I would perform immunoprecipitation to confirm APE1 and
NRF2 binding. In addition, I would need to assess if transcription of known NRF2
downstream targets are decreased in cells with wildtype APE1 as compared to
cells with loss of APE1.
We propose that NRF2 suppresses transcription of DCN, SOD2, and SOD3.
This was supported by our results where we identified negative gene correlation
between NRF2, DCN, and SOD3 (Table 1-2). As previously mentioned in the
discussion section of chapter 1, there are NRF2 binding sites within the promoter
region of DCN, and SOD3 (Table 1-1). Chromatin immunoprecipitation assay
(ChIP) is a technique commonly used to assess binding of proteins to specific DNA
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regions. In addition, transcription of DCN, and SOD3 can be measured using
luciferase promoter assay in cells with wildtype NRF2 and NRF2 knockdown.
These assays combined can confirm whether NRF2 binds to DCN, and SOD3
promoter regions, and whether the presence of NRF2 is associated with decreased
transcription of DCN, and SOD3.
Previous studies have supported that NRF2 suppresses SOD2 (121). We
observed a negative correlation between NRF2 and SOD2 gene correlation in
HNSCC (Table 1-1). However, it is not clear how NRF2 mediates SOD2
suppression. Unlike SOD3, transcription factor binding site analysis demonstrated
no NRF2 binding site within the SOD2 promoter regions. PPARGC1A is a known
transcriptional coactivator of NRF2 (287). If NRF2 is suppressing SOD2 gene
transcription, it is possible that PPARGC1A is modulating this effect. However,
studies have reported a positive regulatory role between PPARGC1A and SOD2
(152). If NRF2 is suppressing SOD2 gene expression, PPARGC1A may enhance
this through acting as an NRF2 coactivator. To examine whether PPARGC1A
enhances NRF2-mediated inhibition of SOD2, transcription of SOD2 should be
assessed using luciferase promoter assay in cells with wildtype PPARGC1A and
PPARGC1A knockdown.
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Appendix C: Supplemental Material for Chapter 1

Supplemental Figure C-1: Ki-67 and Desmin as representative controls for nuclear
and total cellular staining.
IHC for Ki-67 and Desmin were analyzed to determine the accuracy of Aperio’s nuclear,
and the positive pixel count algorithm used for total cellular protein.

173

Supplemental Figure C-2:

APE1 survival analysis:

low versus high protein

expression

Graphs represent the top significant Kaplan Meier survival curves comparing low vs. high
protein expression. Top Row: % Nuclear APE1 protein expression in benign, CIS, and
invasive tissue. Bottom Row: % Total Cellular APE1 protein expression in benign, CIS,
and invasive tissue. * Denotes significance p<0.05 LR: Mantel-Haenszel Log-Rank, GW=
Peto & Peto modification of the Gehan-Wilcoxon statistical tests.

174

Supplemental Figure C-3: PPARGC1A survival analysis: low versus high protein
expression

Graphs represent the top significant Kaplan Meier survival curves comparing low vs. high
protein expression. Top Row: % Nuclear PPARGC1A protein expression in benign, CIS,
and invasive tissue. Bottom Row: % Total Cellular PPARGC1A protein expression in
benign, CIS, and invasive tissue. * Denotes significance p= 0.057 LR: Mantel-Haenszel
Log-Rank, GW= Peto & Peto modification of the Gehan-Wilcoxon statistical tests.
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Supplemental Figure C-4: DCN survival analysis: low versus high protein
expression

Graphs represent the top significant Kaplan Meier survival curves comparing low vs. high
protein expression. Top Row: % Nuclear DCN protein expression in benign, CIS, and
invasive tissue. Bottom Row: % Total Cellular DCN protein expression in benign, CIS, and
invasive tissue. * Denotes significance p<0.05LR: Mantel-Haenszel Log-Rank, GW= Peto
& Peto modification of the Gehan-Wilcoxon statistical tests.
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Supplemental Figure C-5:

SOD3 survival analysis: low versus high protein

expression

Graphs represent the top significant Kaplan Meier survival curves comparing low vs. high
protein expression. Top Row: % Nuclear SOD3 protein expression in benign, CIS, and
invasive tissue. Bottom Row: % Total Cellular SOD3 protein expression in benign, CIS,
and invasive tissue. * Denotes significance p<0.05LR: Mantel-Haenszel Log-Rank, GW=
Peto & Peto modification of the Gehan-Wilcoxon statistical tests.
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Supplemental Figure C-6:

NRF2 survival analysis: low versus high protein

expression
Graphs represent the top significant Kaplan Meier survival curves comparing low vs. high
protein expression. Top Row: % Nuclear NRF2 protein expression in benign, CIS, and
invasive tissue. Bottom Row: % Total Cellular NRF2 protein expression in benign, CIS,
and invasive tissue. * Denotes significance p<0.05 LR: Mantel-Haenszel Log-Rank, GW=
Peto & Peto modification of the Gehan-Wilcoxon statistical tests.
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Supplemental Figure C-7:

Gene expression survival analysis for APEX1,

PPARGC1A, DCN, SOD1, SOD2, and SOD3
Survival analysis was performed and compared low versus high gene expression in
patients with pathology stage T4a HNSCC. Gene expression data obtained from TCGA
database. * Denotes significance p<0.05 LR: Mantel-Haenszel Log-Rank, GW= Peto &
Peto modification of the Gehan-Wilcoxon statistical tests.
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180

Appendix E:

Chapter 1 Summary of Conclusions

Overall protein expression (Figure 1-6):
•

Nuclear and total APE1 increased in CIS and more so in invasive tissue.

•

Nuclear and total DCN decreased in CIS and invasive.

•

Slight increase in total NRF2 in invasive as compared to benign.

•

Nuclear and total SOD3 decreased in CIS and more so in invasive.

•

Nuclear PPARGC1A decreased in CIS and invasive.

Correlation of Protein Expression (Table 1-3):
•

There was a positive correlation with total cellular APE1 and DCN in benign tissue
(p<0.05). However, there was a negative correlation in CIS (p<0.01). This suggests
loss of coordination between APE1 and DCN within the tumor environment.

•

Positive correlation between total cellular PPARGC1A and SOD3 in invasive
(p<0.05) as well as between nuclear PPARGC1A and SOD3 (p<0.01).

•

Positive correlation between nuclear APE1 and NRF2 in benign (p<0.01) and
invasive tissue (p<0.05). Additionally there is a positive correlation between
nuclear APE1 in benign tissue with nuclear NRF2 in CIS (p<0.01). This supports
the link between APE1 and NRF2 expression.

•

There was a positive correlation found between nuclear NRF2 and PPARGC1A
protein expression in benign tissue (p<0.01). This was also observed between
nuclear NRF2 in invasive and PPARGC1A in CIS (p<0.05). Total NRF2 in benign
with total PPARGC1A in benign, and invasive (p<0.01). As well as total NRF2 in
CIS tissue with total PPARGC1A in benign and invasive (p<0.01) as well as CIS
(p<0.05).
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•

A significant negative correlation was observed between total APE1 in benign with
total SOD3 in CIS (p<0.05). Additionally, there was a significant negative
correlation between total APE1 and nuclear SOD3 in benign tissue (p<0.05).

Correlation of gene expression (Table 1-2):
•

Comparing APEX1 in non-neoplastic tissue to SOD3 in non-neoplastic, there was
a negative correlation observed (p=0.09). There was also a negative correlation
between APEX1 and PPARGC1A in non-neoplastic tissues (p=0.095).

•

There was a negative correlation between APEX1 in tumor and SOD3 in nonneoplastic tissue (p= 0.059). There was a positive link between APEX1 with
PPARGC1A in tumor (p<0.05).

•

DCN in non-neoplastic tissue was positively associated with SOD3 in tumor
(p<0.01). This positive correlation was maintained between DCN and SOD3 in
tumor tissues (p<0.01).

•

In non-neoplastic tissue, NFE2L2 had a negative correlation with DCN, SOD3,
SOD2, and PPARGC1A (p<0.01).

Multivariate analysis of clinical factors:
•

Elevated total and nuclear DCN as well as total SOD3 in benign tissue of patients
with poorly differentiated tumors. Decreased PPARGC1A in CIS tissue of patients
with poorly differentiated tumors (Figure 1-10).

•

Elevated total and nuclear APE1 in CIS tissue within the primary tumor of patients
who also had lymph node invasion (Figure 1-9).

Survival Data with Protein Expression:
•

Significantly reduced survival in patients with high total APE1 in CIS tissue (LR
p=0.0243, GW p=0.0326) (Figure 1-7).

•

Patients with high total PPARGC1A in invasive tissue had significantly reduced
survival (LR p=0.0281, GW p=0.0575)(Figure 1-7).
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•

High nuclear DCN in benign tissue was linked to reduced survival (LR p=0.0493)
(Figure 1-7).

•

Low levels of total SOD3 in invasive tissue was linked to reduced survival (LR
p=0.0797, GW p=0.0377) (Figure 1-7).

Survival data based on gene expression in T4a HNSCC
•

Significantly reduced survival with high APE1 gene expression in pathology stage
T4a tissues (LR p=0.0148, GW p=0.0101) (Figure 1-8).

•

There was no significant difference in survival in the gene expression of NRF2,
DCN, PPARGC1A, SOD1, SOD2, or SOD3 in pathology stage T4a tissues (Figure
C-7).
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